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SUMMARY 
Six pyrimethaznine-resistant lines were obtained 
by selection from 3 strains of Plasmodium berghei yoelii 
and one of P,berghei nigeriensis. Two of the resistant 
lines were isolated from cloned parasite material, while 
a further two were derived from U.V.irradiated parasite 
material. 
An attempt was made to measure the frequency 
with which pyrimethamine-resistant lines appeared in 
the selection system. 
The six pyrimethamine-resistant lines and the 
three parasite strains from which they were derived 
were characterised for a number of parameters. 
The characterisation studies suggested that the 
pyrimethainine-resistant lines were of two types, either 
cross-resistant to suiphadiazine and of low dependenoe 
on PABA for growth, or sensitive to sulphadiazine and 
highly dependent on PABA for growth. Only one resis-
tant line was obtained with the first type of resistance. 
An investigation of the stability of resistance 
of the six pyriiuethamine-resistant lines after blood 
and mosquito passage, and storage in liquid nitrogen 
gave no indication of any change in degree of 
resistance due to these treatments. 
An analysis was made of a cross carried out 
between line 17X (pyrimethamine-sensitive and GPI-1 
type) and line 33X(Fr3) (pyrimethamine-resistant and 
GPI-2 type). 	Forty product clones were derived from 
the product of this cross. 	Parasite clones with 
parental and recombinant combinations of characters were 
obtained. 	An attempt was made to analyse the segre- 
gation patterns of development site and FABA dependency 
characteristics of the product clones. Both these 
characters appear to segregate without the pyriniethamine-
response marker during a cross. 
An analysis was made of the response to pyrimeth-
amine of product clones derived from a cross between 
the N67 (pyrimethamirie-sensitive and GPI-2 type) and 
line 17X(Prl) (pyrimethamine-resistant and GPI-1 type). 
Only two classes of product clone were obtained with 
respect to their response to pyrimethamine, namely a 
resistant and sensitive class. 
A discussion of the selection experiments, the 
characterisation studies, and the crossing experiments 
is included. Future developments in genetic studies 
with malaria parasites are also considered. 
INTRODUCTION 
In 1948 the establishment of the World Health 
Organization by the United Nations made international 
malaria control possible. At that time the prospects 
for malaria eradication schemes seemed highly promising o  
combining mass chemotherapy with vector control • This 
policy has not with some success: the islands of Ceylon, 
Mauritius and Cyprus have eradicated malaria, while 
India is said to be virtually clear of the disease. 
However, in Africa, South East Asia and South America 
malaria remains a common disease. It has been estimated 
that current eradication programmes protect 619 million 
people and substantial anti-malarial operations affect 
a further 195 million, but 272 million people still live 
in malarious areas where no specific anti-malarial 
measures are being carried out (from W.H.O., 1971 and 
summarised by Peters, 1972). The failure of the eradi-
cation programme has been associated with administration 
problems and the growing incidence of drug-resistant 
strains of malaria vectors and malaria parasites. 
The appearance of drug-resistant plasmodia occurred 
at the end of the 1940s: four years after the introduction 
of proguanil into the field, infections resistant to the 
standard drug doses were reported. The evidence for this 
development came from both field investigations and lab-
oratory studies in animal and human malaria*. The first 
field report came from Malaya (Field & Edeson, 1949) 
where, in 1947, mass administration of proguanil for 
2. 
prophylaxis purpose, was introduced on a rubber plant-
ation. A high level of drug-resistance in strains of 
P.falciparua was evident by 1949. Similar findings soon 
followed from Assam and Indo-china( Gilroy, 1952 and 
Canet, 1953). 
Pyriaetham{ne is reputed to have been designed on 
the basis of its structural resemblance to cycloguanil 
(which had been identified as the active metabolite of 
proguanil), and was introduced as an antimalarial 
agent in the field in 1952. The first indication of the 
ease in which pyrimethamine-resistant strains could occur 
in the field came when McGregor and Smith (1952) reported 
that pyrimethamine in repeated doses had failed to cure 
a Lalciparum infection in the Gambia. Subsequently, Jones 
(1954 & 1958) reported the appearance of strains of P. 
falciparum and P.aalariae which had become resistant to 
pyriaethaaine in the Makueni region of Kenya. Afridi and 
Rahim (1962) reported the appearance of pyrimethamine-
resistant P.falciparua in West Pakistan, while Maberti 
(1960) reported the occurrence of pyrimethaaine-resistant 
strains of P.falciparua and P.vivax in Venezuela. Many 
other reports of pyriaethamine-resistant strains of P. 
falciparum have now come from both Asia and Africa, and 
these have been summarised by Peters (1970a). 
These developments were not, howe*er, considered 
to be too serious for malaria chemotherapy, since aepa-
crime and the 4-aminoquinolines such as chloroquine 
were thought to emulate quinine in being unable to 
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induce drug-resistance. This view was supported by 
numerous, unsuccessful attempts to induce chioroquine-
resistance in various animal plasmodia, as well as one 
such attempt with Pvivax. Chloroquin.-resistant strains, 
however, were reported in 1961 in Columbia with P. 
falciparun (Moore & Zanier, 1961, and Young & Moore 1961), 
and other reports from the Par East and South America 
have since followed. The development of chioroquine-
resistant plasdia1 strains was not well documented. It 
is now known that strains of P.falciparws vary greatly 
in their degree of sensitivity to chioroquine (Peters, 
1970a) and it cannot be ruled out that the current sit-
uation is due to the existence of strains of P,falciparum 
whose sensitivity to chloroquine has always been con-
siderably less than the more commonly encountered strains, 
rather than to the emergence of new resistant lines under 
the influence of drug use. 
The increase in the incidence of drug-resistant 
malaria has increased the need for research into malaria. 
The United States of America, with its recent military 
involvement in South East Asia, an area where drug-
resistance has become a serious problem, has undertaken 
a massive drug screening scheme, screening a thousand 
chemicals weekly. New compounds with some degree of 
anti-malarial activity in the test systems have been 
discovered, and these are undergoing or awaiting field 
trials (Aviado, 1969). The limited success of this 
screening scheme has increased the importance of research 
4. 
into the development of resis tame and the nechanisas 
underlying the action of the standard antinalarial 
drugs, $ uch as pyrias thanine, pro guani 1, chioroquin., 
amodiaquine and primaquin.. It has also increased inter-
est in studies on the biology of the malaria parasites, 
as these may help to locate differences in the metabol-
ism of the host and parasite and allow a less haphazard 
approach to the development of new drugs or other anti-
malarial measures, than occurs at the present tin.. 
The present study uses a genetic approach to 
investigate pyriai.thsnine-r.sistance in rodent malaria. 
It is important when contemplating genetic experiments 
with malaria parasites to choose characters for study 
which are known to be stable during blood passage and 
mosquito transmission, and for which simple tests can 
be devised to distinguish between the various parasite 
forms because in genetic studies of malaria parasites 
It is necessary to analyse a large number of clones 
derived from the products of a cross. 
Resistances to antifolates were considered partic-
ularly suitable for genetic investigation because of 
the reports in the literature of their stability during 
both blood passage and mosquito transmission. For 
example, Bishop and Burkett (1947 & 1948) produced a 
line of P.gallinaceua resistant to proguanil, by gradually 
increasing the drug-selection pressure over 4 months. 
They reported that a sub-line was found to retain its 
resistance through 5 sequential mosquito transmissions 
S. 
interspersed with blood passages through untreated chicks. 
This procedure lasted 3 months during which time the 
sub-line was completely free of any contact with proguanil. 
Subsequently, Bishop and McConnadiis (1950 ) repeated 
this type of experiment on a further sub-line of the 
proguanil-resistant line of P.a11inaceum. ibey passaged 
this sub-line 140 times through untreated chicks doing 
52 weeks without recording any loss of resistance to 
proguanil. Similarly, Greenberg and Bond (1954) have 
recorded that their pyrinetbaains-resistant P.gallinaceun 
line maintained its resistance for at least six months 
while not receiving drug pressure. 
This behaviour of pyrimethamina and proguanil 
resistant plasaodia contrasts sharply with that of 
chloroquine-resistant lines which have frequently proved 
to be unstable (Raaakrishnan et *1 (1957), Kollert (1963)9 
Jacobs (1965)0 Thompson *t al (19653), Peters (1965d) and 
Hawking (1966). Peters(1968a and 1968b) has carried out 
an extensive study of the loss of cbloroquine-xesistance 
during blood and mosquito passage without contact with 
the drug. 
Resistance to antifolate drugs would also appear 
to be relatively easy to obtain. For example proguanil' 
resistant lines have been developed by a large number 
of workers including: Bishop and Birkett (1947), 
Williamson at al (1947), Knoppers (1947)9 Rollo (1955a) 
Greenberg (1949) - all in ?.jallinaceua; Redmond and 
Pincher (1949), Grant (1950) in P.relictua; Thompson 
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et a]. (1948) in P.lophurae; Hawking and Perry (1948) and 
Schmidt et a]. (1949) in P.cynomolgi; Haswant Singh et a]. 
(1952b) in P.knowlesi, and by Rollo (1951) and Sautet 
et a]. (1959) in P,berghei. Similarly, many pyrinaethamine-
resistant lines have also been obtained in P.gallinaceum 
(Rollo, 1952a and 1952b; Jaswant Singh et a]. 1952a - 
these workers also showed that the resistance extended 
to the pre-erythrocytic stages; Greenberg and Bond, 1954; 
Bishop, 1962 - Beaudoin et a]. (1967) used this strain 
to demonstrate that resistance extended to the secondary 
exoerythrocytic stages; Rabinovich, 1965b and Richards, 
(1966b), in P.lophurae (Trager, 1961), in Pberghei 
(Rollo, 1952a and 1952b; Thurston, 1953; Jacobs, 1964; 
Rabinovich 1965a and 1965b; Vincke, 1966; Benazet and 
Werner, 1968 and Thompson and Bayles, 1968), in 
P.cynomolgi (Schmidt and Genther, 1953, and Jaswant Singh 
et a]., 1953), and in P.kr*owlesi (Jaswant Singh et a]., 
(1954a). While in human malarias, Hernandez et al (1953) 
were the first to report inducing experimental pyrimeth-
amine-resistance in P.vivax and Young (1957), and Burgess 
and Young (1959) reported inducing this drug resistance 
in strains of P.malariae and P.falciparwu. 
It was also thought that resistance to pyrimethamine 
would be particularly easy to obtain as it is possible 
to subject large parasite populations to asirigle session 
of drug treatments which will invariably eliminate all 
the drug-sensitive parasites which are present and there-
by allow resistant parasites to be readily identified. 
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Bishop (1963) concluded that high doses of drug did 
not prevent the development of resistance to either 
progusnil or pyrimethamine, as had been suggested by 
Covell et .1 (1953)9 and in fact Diggen. (1970) obtained 
a pyri.sthaains.resistsnt line of P.berghei after 
subjecting infected hamsters to a daily dose of 200 ag/kgm 
of pyrimethamine for 4 consecutive days. Resistance to 
drugs such as chloroquine would appear to be more diff-
icult to obtain by selection than resistance to the 
antifolate drugs. For example Thompson et al (1948), 
Schmidt at al (1949) Bishop and McCorinachie (1952)0 
Seaton (1951), Kollart (196), Hawking (1966) and Bishop 
(1967) have all reported some failed attempts at induc-
ing chioroquine resistance. In addition, successful 
attempts have been characterised by a very slow build 
up of the chloroquine-rasistance at least during the 
early blood passages under drug pressure. It should be 
noted however that a number of reports have been pub-
lished concerning failure to induce resistance to anti-
Lolate.. For example, Benazet (1964) and Bishop (1966a) 
reported that not all the sub-lines they exposed to 
cycloquanil yielded resistant limes. 
Of all the resistances obtained to antifolate drugs 
used in malaria chemotherapy, resistance to pyria.thaaine 
was considered of particular interest for genetic studies 
because of the reports of Greenberg and Trembley (1954b) 
and Yoeli et al (1969) that this resistance could be 
transfered. However, the evidence presented for hybrid- 
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ization by Greenberg & Trembley and synpholia by Yoeli 
et al is not considered conclusive and will be discussed 
in some detail later. 
In addition, the reports that pyrimethamine resis- 
tance was associated with an increased requirement for 
MBA (Jacobs, 1964) and a decrease in the ability of 
the parasite lines to live in mature erythrocytes 
(Arnold, 1967) added extra interest to the study of this 
character. 
A considerable amount of research concerning the 
biochemical basis of the action of pyrimethamine has 
also been carried out. A brief review of this is now 
presented. Pyrimethamin* was developed as an anti-malarial 
drug during the 1950s. At that time it was already 
known that drugs of this type affected folic acid metab- 
olism (reviewed by Hitchings, 1960 and 1971), although 
it was not known precisely how the drug caused the death 
of the parasite. In most organisms folic acid meta- 
bolism is concerned with the transfer of one carbon 
units in the synthesis of vital cell components, such as 
DNA bases and amino-acids (reviewed by Huennelcens & 
Osborn 1959, and Mudd and Cantoni, 1964). Briefly, 
folic acid metabolism can be divided into three parts: 
(i) the production of t.trahydrofolic acid (FH4) from 
folic acid or its component parts; (ii) the production 
of a large number of folate coenzymes from FH4, and 
(iii) the involvement of these foiste, coenzymes in the 
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synthesis of purines, pyrimidines and amino acids. 
Plasmodia lack a folate reductase and are therefore 
unlike their vertebrate hosts in that they cannot 
synthesise FR4 directly from folic acid (Ferone & 
Hitchings, 1966). Fig.l. illustrates the difference in 
FR4 production pathways of plasmodia and higher organ-
isms. 
In an attempt to define more precisely the nature 
of pyrimethawine inhibition of parasite metabolism, 
Ferone at al (1969) 9 isolated F.berghei dihydrofolate 
reductase, and demonstrated that its catalysis of the 
reduction of dihydrofolate to FH  was inhibited by pyri-
aethne, and by a structurally related drug, trimetho-
prim. significantlyg there was a correlation of the 
degree of enzyme inhibition by these two drugs in vitro, 
and their relative effectiveness in vivo. Furthermore, 
they showed the parasite enzyme to be much more sen-
sitive to pyrinethamine than the host dihydrofolate 
reductase • From these results Ferone, Hitchings and 
aurchali suggested the potent inhibition of dihydrofolate 
reductase to be the basis of the anti-malarial action 
of pyrimethanine. 
At the present time there is disagreement as to 
the most important biochemical consequence of inhibition 
of this enzyme. Huennekens at al (1971) 0 and Platser 
(1972) suggest that it would prevent DNh replication by 
stopping the synthesis of thymidylate. In free-living 
organisms the synthesis of purines and some amino acids 
Fig,i. 	Folate Coenzyme Production 
Folate reductase 
PAM + pteridine condensing system 
Dihydrofolate reductase 
Systems for the production of the folate coenzymes 
(B) 	Involvement of the folate coenzymes in one carbon 
unit transfer reactions 
VERTE.BRATE HOST 
Folic acid 	1 ; 
>FH4 —? - - Folate 
coenzymes 
+ pteridine 	:, 	 \ \ \ 
PLASMODIUM 
From: Ferone & Hitching (1966), with modifications 
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also involves folate coenzys. However, malaria parasites 
obtain these compounds from their hosts (Moulder, 1962; 
P01st & Conrad, 1969; Cenedeila et *1., 1968; Sflngener 
& Nielsen, 1967 & 1968; Walsh & Sherman, 1968; 
Gutteridge & Trigg, 1970; Trigg & (3utteridge, 1971, and 
Platzer, 1972 - although there has been one report by 
Siddiqui et al., 1969, which suggested that P.knowlesi 
requires exogenous pyrimidines for development in vitro), 
and therefore the avilability of these substances to 
plasmodia would be unaffected by disruption in the pro-
duction of Lolate coenzymes. in keeping with this 
hypothesis, Schellenberg & Coatney, (1961), found that 
pyrimethamine specifically inhibited the incorporation 
of P32-phosphato into DMA. 
Other workers have described results conflicting 
with the hypothesis that pyrimethamine prevents the 
synthesis of thymidylatez Aikawa & Beaudoin (1968) pre-
pared electron micrographs of P.9l1inaceua erythrocytic 
schtzonts which had been treated with pyriaethsaine. 
These revealed a large number of schizonts fixed at the 
metaphase plate stage of nuclear division. DNA synthesis 
occurs throughout schizont maturation and is completed 
by prophase within each phase nuclear division (Gutteridge 
& Trigg, 1970). These results suggest therefore that 
pyriaethaaine acts highly specifically in blocking cell 
division after the completion of DNA replication. 
Furthermore, Gutteridge & Trigg (1971) observed that the 
inhibition by pyrimethamine of the incorporation of 
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phosphate into parasite DNA did not take place until 
after the time when schizonts in undrugged cultures of 
P.knowlesi had segmented and entered further host cells. 
They suggest therefore that there is some other metabolic 
process requiring a fully functioning dihydrofolate 
reductase during schizogony. Of interest to this point, 
Dicicerman (1971) has demonstrated that the synthesis of 
formylated methionine required by Escherischia coli for 
the initiation of protein synthesis, involves folate 
coenzymes. 
Even though pyrimethamine is known to inhibit 
dihydrofolate reductase activity, it is still possible 
that other target sites for this drug exist in plasmodia. 
Of interest to this point is the demonstration by Ilan 
et al (1969) that pyrimethamine also inhibits the 
P,bergei enzyme associated with the coupling of valine 
to a transfer RNA molecule. 
In conclusion, it can be seen that we are still unable. 
to decide how a restriction in the production of tetra-
hydrofolic acid, due to the action of pyrimethamine, leads 
to an inhibition of parasite replication. More information 
is required on the basic biochemistry of the parasite and 
in particular on how it synthesises thymidylate and what 
other synthetic pathways require folate coenzymes. 
In view of the confusion concerning the precise 
nature of the anti-malarial action of pyrimethamine, it 
is difficult to formulate or evaluate hypotheses of the 
12. 
mechanisms which eight produce pyr ins thamine -resistance. 
Hwever, biochemical studies have been carried out on 
pyrieethamiz* -ree tant P . berhei parasites (Ferone, 
1969; and Ferone et &I t 1970), and these suggest that 
dihydrofolate reductases isolated from pyrimethamins 
resistant and sensitive parasite lines have differing 
kinetics and pyriasthamine inhibition coefficients. 
Diggens et al (1910) have carried out a similar study 
with another pyrimethaaine-resistant line, and have also 
reported altered enzyme kinetics associated with the 
dihydrofolate reductase isolated from their pyrinsth.wine-
resistant line. 
The main purpose of the resevc progranime reported 
in this thesis was to carry out genetic studies on 
pyrime thamine- resis tance of p laseodia. Accordingly, a 
number of lines were developed which were more resistant 
to the action of the drug than the original parasite 
strains from which they were derived. During, the course 
of. this study it was suspected that further differences 
existed between the pyrimethine-resistant lines. Due 
to the lack of resources available it was not possible 
to carry out a thorough examination of all aspects of 
these additional characters. However, an attempt was 
made to devise a Set of simple tests which could identi-
fy clearly the differences existing between parasite 
lines and which would also be of use in genetic analysis. 
It was hoped that the study of these additional 
characters might facilitate the genetic analysis of 
pyriasthaaine-resistance. 
13. 
'VA' 	St MJTH(S 
(1) Isolate&,  strainsand lines of Plasmodium (Vinckeia] 
berghei Vincke and Lips 1948. 
(a) Definition of terms 
The application of these terms to malaria parasites 
in our laboratory was first defined by carter (1971). 
Isolate:- The term "isolate" is applied to parasites 
derived from a single wild host specimen on a unique 
occasion. 
Strain:- The term "strain" is applied to all parasites 
of a single sub-species present in an isolate. 
Stabilate:- Luinsden and Hardy (1965) defined the term 
"stabilate" as, "A population of an organism preserved 
in a viable condition on a unique occasion. There will 
be only as many examples of a stabilate as there were 
individual samples of it laid down on the unique 
occasion. It will therefore be possible to designate 
each stabilate by a unique code letter or number". 
Line:- The term "line" is applied to parasites derived 
from a single strain on a specific occasion. 
By strict definition every laboratory manipulation 
of a strain involves the creation of a new line of 
parasites. Thus each time blood is passaged from one 
infected animal to another a new line is formed. In 
general, however, parasites are referred to as a line 
m, i U)flI 	I. N. W. 
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only after a strain has been subjected to a special 
form of manipulation or treatment. For instance, it 
is con practice to refer to a "drug-resistant line" 
of parasites, such a line having been derived from a 
drug-sensitive strain: parasites derived from a single 
sample of a deep frozen stabilate are usually referred 
to as a "line". 
jb)Th.oriinsjolates,, strains and lines 
Table 1 lists the isolates and strains of Pies- 
sodium berghsi studied in the present work. 	Table 2 
lists the pyrimet)saine-resistant lines derived in this 
laboratory. 
I an indebted to the following for the provision 
of parasite material: to Professor A.G.Chabad and 
Madame I,Landau for strains 17X and 33X (the stabilates 
held at Edinburgh were obtained from the London School 
of Hygiene and Tropical Medicine); to Dr R. Ki]lick-
Kendrick for strain N67 and to Mr Soulard who collected 
the tree rat in the Central African Republic from which 
strain 15IBY was derived in our own laboratory. 
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Table 2. The pyraainer!sist ant lines derive 
in this laboratory. 
Pyriaethald.ne . Obtained from date of 
resistant line strain production 
17X(Prl) 17X June 1970 
N67(Pr2) N67 June 1970 
33X(Pr3) 33X June 1971 
33X(Pr4) 33X Jun. 1971 
17X(Pr5) 17X November 1971 
N67(Pr6) N67 November 1971 
The pyrimethamine-resistant lines were named as follows: 
the name of the original sensitive strains from which 
the line was derived is retained, the Pr suffix denotes 
the pyrimethamine..resistance; the numeral indicates the 
order in which the various lines were obtained. 
Host sjcias used in the laboratory 
Table 3 lists the rodent and nosquito species used 
in these studies. 
Maintenance of malaria 	in the laboratory. - 	--- -- -- - ---------- 
(a) Preservation in liquid nitrogen 
Stabilates of infected blood were stored in sealed 
capillary tubes kept in liquid nitrogen, alter the 
method of Lumsden at .l (196). 	Blood infections were 
derived from this material by the intraperitoneal 
inoculation of the thawed contents of a capillary tube 

































(b) Blood passaqeof malaria parasites in laboratory 
rodents. 
Malaria infections were maintained in the Lab-
oratory by inoculation of blood from infected rodents 
into uninfected rodents. The infected blood was diluted 
in citrate saline (0.9% MaCi, 1.59 Na citrate, adjusted 
to pH 7.2) and about 0.1 ml of the diluted blood 
inoculated into each animal. This procedure is termed 
"blood passage". 
Infected mice were routinely supplied with drink-
ing water supplemented with a 0.05% p-minobenzoic acid 
(PAM) to promote high parasitaemia (Hawking 1953). 
Mice were maintained on this dietary regime for not less 
than 7 days before they were inoculated with parasites. 
The experimental results which lead to the adoption of 
this level of PAM supplementation are included in 
Appendix A, page!23. 
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(c) Cyclical transmission of malaria parasites 
Mosquito passage was conducted after the method 
of Landau and Killick-Kendrick (1966). Parasitised 
blood from an infection generally not more than 5 blood 
passages from a sporozoite-induced infection, was 
inoculated into a mouse or thicket rat. Four days 
after the inoculation the animal was placed in a cage 
of unfed, 7 to 14 day old Anopheles stephensi. When 
the mosquitoes had stopped feeding, the animal was 
removed from the cage. The next day a 10% solution of 
glucose supplemented with PAM was provided as a food 
source for the mosquitoes. The mosquitoes were main-
tained at 25°C and 909 humidity, with alternating 12 hour 
sequences of light and dark. 
Five days after the blood feed, a sample of the 
mosquitoes were dissected to count the number of oocysts 
developed on each gut. 
Ten to 14 days after the blood feed, when sporo-. 
zoites were seen to be present in the salivary glands, 
these glands and the midguts were dissected into cold 
tissue culture medium consisting of modified Kitamura's 
medium and V. P.12 medium (Pudney and Varna 1971). 
The number of mosquitoes dissected ranged between 
10 and 40, depending on the level of infection recorded 
in the mosquitoes. The mosquito tissue was broken up 
with a teflon pestle and about 0.2 ml of the suspension 
inoculated into a rodent by the intravenous route. 
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Patent blood infections could be detected 4 to 6 days 
after the sporozoite inoculation. 
Red blood cell counts 
These counts were carried out using a haemocyto-
meter, in blood which had been diluted in citrate 
saline. 
" parasitaemia" counts of infected bloud. 
A thin, tail blood smear was prepared, fixed in 
methanol and stained with Giemsa's stain. Whilst making 
the smear care was taken not to force blood from the tail 
as this can produce a sample of blood containing a 
higher proportion of infected cells than is present in 
the rodent host, due to forcing out any large parasites 
adhering to the walls of the tail blood vessels. 	In 
addition, counts were only made in the central area of 
the blood smear, as frequently the 'tail' and edges of 
a smear will contain a higher proportion of parasitised 
erythrocytes than the rest of the smear. 
To standardise the errors due to sampling while 
estimating parasitaemias, calculations were carried out 
to determine the number of red blood cells to include 
in the sample to give a reasonable level of error at 
different parasitaemias. Dr Hayter of the Institute 
of Animal Genetics produced the following formula:- 
Let n = total number of red blood cells counted 
x = % parasitaemia 
Y = "acceptable" limits chosen 
s.e.= standard error 
Tsblø 4. Red blood cell counts at different 
Parasi tasnia levels. 
Parasitaeaia + 2 s.c. 	Number of RI3C to 
- 	 be counted 
L_ 
0.014 + 0.02% 	 109 000 
0.1% 0.06% 10,000 
1% 0.03% 5 0000 
10% 1.1% 3,000 
30% 2.0% 1 9 600 
3096 + 3.0% 1 0000 
60% 3.5% 800 
70% 3.5% 800 
ZL 
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Thus x + 2 see. x + x + y 
100 
s.e.E 	(1 -x )Yx 
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By substituting a variety of values for x and y into the 
formula (i.e, chosen"acceptable" levels of error (y), 
at specific parasitaesias (x)), table 4 was drawn up. 
The largest sample size was arbitrarily fixed at 
10,000 red blood cells. The use of table 4 is illustrated 
by the following: if a count of a small sample of cells 
from a smear gave a parasitasmia of around 10%, then the 
original sample was extended to include an estimated 
3 9000 red blood cells. The erythrocytes were estimated 
by each microscope field in terms of 100, 150 or 200 
cells, by inspection based upon much experience in 
actual counting. 
(6) Preparation of a standardised inoculun of Malaria 
parasites. 
Frequently experiments required large numbers of 
mice to be inoculated with a standard number of parasites 
originating from a single donor. In such cases a red 
blood cell count and a parasitaeaia count were carried 
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out on a sample of the donor's blood. The subsequent 
preparation of the standardised inocula depended on 
the size of the inocula required. 
An inoculum size of lO or 10 parasites per 
mouse: 
The donor rodent was bled from the brachial 
vessels, the blood being collected with a pasteur pipette 
or syringe containing a drop of heparin. The blood was 
then diluted in serum Ringer (50 v/v calf serum in 
Ringer's solution:- KCl; 0.2gm, CaC12; 0.29m, NaCl: 9gx, 
Distilled water: 1 litre, Warhurst & Foiwell, 1968). 
The dilution step was carried out so that the required 
number of parasites could be inoculated in a 0.1 ml 
volume. 
An inoculum size of I or less parasites per mouser 
Occasionally it was required to obtain blood infec. 
tions derived from a single blood parasite. After 
attempts at cloning by micromanipulation had proved 
unsuccessful, a method of "cloning by dilution" was 
adopted. 
The procedure for the "cloning by dilution" method 
was as follows: a 52\ sample of blood was collected 
from the tail of the donor rodent and diluted in 1. ml 
of serum Ringer. Further dilution steps were then made 
until the parasite concentration was 5 to 7.5 per ml. 
0.1 ml aliquots of this suspension were inoculated intra-
venously into a group of 20 to 30 mice. If it is 
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assumed that the distribution of the diluted parasit-
ized erythrocytes to the inoculated mice conforms to a 
Poisson distribution, then it follows that if one in 
three (or less) of the inoculated mice become infected, 
on average 80% (or more) of these infections will have 
originated from one parasitized erythrocyte (Carter: 
unpublished information). To reduce the possibility of 
infections arising from doubly infected erythrocytes, 
donor animals were chosen with very low parasitaemias, 
for in these double infection of red blood cells is 
rare. If more than one third of the mice became infectc 
it was probable that the inoculum contained more than 
on average one parasite and the experiment was discarded. 
(7) The source, Rre2aration and administration fds 
(a) Pyrimethamino 
Source: Pyrimethamine (Daraprlm, 2, 4 diamino-
5-p-chlorophenyl-6-ethyl-pyrim.idine) in the form of 
powdered base was obtained from the Wellcome Research 
Laboratories, England by courtesy of Dr. R.A.Neal. 
Calculation of drug dose: drug dose was related 
to the mean weight of a group of experimental mice. 
The unit of dose was mg/kgm body weight. These cal-
culations were made in order that a given amount of 
drug could be injected in a 0.1 ml volume. 
The preparation and administration of thtAEMI  
suspensions: Two methods were used and it will be 
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indicated in other sections of this thesis which of 
these methods was used during a particular experiment. 
The methods were as follows : - 
The method of Yoeli et al (1969). A suspension of 
250mg/mi of pyrimethamine in distilled water was made, 
to this was added one drop of Tween 80 per 10 mis of 
suspension. The suspension was sonicated for 5 minutc. 
Further dilution from this stock was made with a 276 
solution of sodium carboxymethyl cellulose. Drugs were 
thoroughly shaken on a vortex mixer immediately prior 
to their administration to mice. 
This preparation was given to mice by the subcut-
aneous route. Control mice were given ca.rboxymethyl 
cellulose. 
After receiving advice from Dr. R.A.Nea]., of the 
Wellcome Research Laboratories, pyrimethamine was admin-
istered by the oral route in view of the more regular and 
complete absorption of the drug by this route. The 
method used for preparing solutions of the drug for 
this route of administration was as follows: the quantity 
of pyrimethamine required was weighed and diluted with 
a weak solution of acetic acid, and a 2% solution of 
carboxymethy]. cellulose. The ratio of volumes of these 
two solutions was 1:5. Drugs were thoroughly shaken on 
a vortex mixer before administration to mice. 




Source: Sulphadiazine (2-sulphonamido-pyrixnidin€) 
in the form of a dry powder was obtained from May & 
Baker, England. 
Calculation of drug dose: As with pyrimetha-
mine, doses of suiphadiazine were related to the mean 
weight of the experimental mice to be injected 
Thejeparation and administration of suiphad-
diazine. A stock solution of suiphadiazine at a con-
centration of 20 mg/ml was prepared by dissolving the 
powder in iN NaOH and adjusting the pH to 9.6 - 9.8 
with iN HC1. Further dilution from this solution was 
made with NaCl at pH 9.6. 
The diet of experimental mice used in su]phad-
iazine studies: Suiphadiazine is antagonised by PABA, 
therefore when mice were required for sulphadiaziiae 
studies, their drinking water was supplemented with only 
a 0.005% solution of PABA (instead of the standard lab-
oratry regime of a 0.0596 PABA solution). This dietary 
regime was started when the mice arrived in the labor-
atory, and all mice were maintained on this level of 
supplement f or at least 7 days before being inoculated 
with parasites. 
An evaluation of the use of this dietary regime in 
conjunction with suiphadiazine is given in a later part 
of this thesis, page 102. 
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(8) The selection of pyriasthamine-resistant lines of 
F.berghei. 
The parasite material for these experiments was of 
three types: a) normal, untreated parasites derived 
from a wild rodent and thereafter maintained by blood 
and cyclical passage; b) parasites recently cloned by 
dilution; and C) parasites which had been QV. treated. 
A "tingle step" method similar to that used by 
Diggens (1970) was adopted. Pyrimethamine-sensitive 
parasites were harvested from 2 to 12 mice • The para-
sites were diluted in serum Ringer and inoculated into 
10-60 nice by the intraperitoneal route. When the para 
Si te inoculations had been completed an estimate was 
made of the number of parasites inoculated per mouse, 
by carrying out red blood cell and parasitasnia counts 
on the diluted blood. 
Pyrime thamine was given for four consecutive days 
commencing 0-8 days after the parasite inoculations. 
Daily doses of between 50 and 200 ag/kga were gin. 
The drug was administered sometimes by the subcutaneous 
and sometimes by the oral route. The route of admin-
istration in individual experiments has been specified 
in Table 6, in the Results Section. 
An estimate of the mean number of parasites present 
per mouse on the day of commencement of drug treatment 
was calculated from: a) the mean parasitaemzL taken from 
the blood smears of a sample of five mice: b) a red blood 
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cell count of the mouse whose parasitaewia was closest 
to the mean value obtained for the group, and c) the mean 
blood volume (the estimate of this latter value ranged 
from 3 to 5 mle and depended on the size of the infected 
mice). 
If the parasite inoculations and the first drug 
injection occurred on the same day, the number of para-
site* inoculated per souse was taken as the estimate 
of the number of parasites present at the start of the 
drug treatment. 
The selection experiments were followed by exam-
ining individual blood smears, S. 12 and 21 days after 
the completion of the drug injections. Mice which were 
infected on days 8 or 12 were sacrificed and a supp-
ressive test carried out with the harvested parasites, 
in fresh mice. 
(9) UV irradiation of blood-form malaria aras&tes 
The UM source was a Phillips T.U.V., 15 watt, 
medium-pressure, mercury-vapour lamp, 90% of its out-
put being at 2537 R. Doses were measured using a 
"Jagger Meter". The dose rate was 28 ergs/on 2/sec, 
variation in dose being obtained by altering the UV 
exposure period. 
Parasites to be irradiated were collected from the 
brachial vessels of a group of well-infected mice and 
suspended in citrate saline. A brown layer parasite 
concentrate was then obtained (p. 	36 ) which was 
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resuspended in 30 mis of phosphate saline, pH 7.4 
with glucose (Krebs & Eggleston, 1940). This solution 
was made up in the following way: 52.5 mis of Krebs 
solution. (50 mis, 1.8%NaC1; 2m1s 3.04 KCl..; 0.5mls, 
7.68% NgSO4.71120 ), 52.5 mls of a 10% Glucose solution, 
30 mis of a phosphate buffer pH 7.4 (24.3 mls,0.2H 
Na2H*'04; 5.7 mis 0.2t4 NaH2PO4). Aliquots of this sus-
pension were kept on ice. 
(a) The production of a U  ,V, dose-response curve 
It was necessary to obtain a dose response curve 
of Uy dose against parasite viability, fore sub-
jecting large numbers of parasites to UV. irradiations. 
The aliquots of the concentrated parasite suspen-
sion were given varying doses of U.V. ranging from 0 to 
7 0,000 ergs/u=2. During the irradiation period the 
parasites were kept in shallow, iced petri dishes and 
were constantly stirred. Parasite viability was measured 
using the modified Warhurst bioassay (p,33 ). For 
this test identical numbers of parasites from each 
aliquot were inoculated into four mice • The mean length 
of time was recorded for the mice in each group to 
exhibit a 1A parasitaeaia. It was assumed that this 
time interval was directly proportional to the number 
of viable parasites originally inoculated, and therefore 
an estimate was possible of the number of parasites 
which had been eliminated by each tN treatment • 	It 
was assumed that U.V. acts by killing a percentage of 
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parasites rather than causing a period of pre-patent 
slowed growth. 
The dose-response curve obtained is included in 
the Results section (p. 49). 
() TJ irradiation of blood-form RMasites prior to 
selection experiments. 
For pyrimethamine selecti;n experiments, the ali-
quots of concentrated parasite suspensions all received 
5,000 ergs/Mm 2 of U31 • The conditions of the parasites 
during the irradiation period were the same as those 
of the parasites used in the production of the UV dose-
response curve. 
After UV treatment, the parasites were pooled and 
inoculated into mice. The time interval between har-
vesting the parasites and the inoculation of the 
irradiated parasite population into experimental mice 
was 21 hours. Thereafter the experiments followed the 
course of the standard pyrimethaniine selection experi-
ments. Several day3 were allowed to elapse before 
the commencement of drug treatment. 
(10) Drug tests of the blood-form of malaria parasite 
A number of drug tests were investigated in this 
study. The primary aim was to develop a test to diff-
erentiate 
-.
i te between the responses of a number of recently 
isolated P.berghei strains and lines, which would 
balance the need for a precise and repeatable test 
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against the necessity in genetic work of a simple and 
quick test to allow a large number of lines to be 
tested by one person. 
Peters (1970a) has drawn up a list of the factors 
which must be standardised in an in vivo drug test on 
the blood forms of rodent malaria. These are as follows- 
mouse strain 
sex and age of mice 
concomitant infections in mice - the effects Of 
Eperythrozoon coccoides and Haemobartonelia muris 
on the course of plasmodium infections has been 
well documented( Kretschmar, 1963; Peters 1963 
& 1935a; Ott and Stauber, 1967, and BUngener, 1968). 
environment - in relation to temperature, stress 
and PABA levels. 
time required for preparing inocula 
route of administration of drug 
timing of first drug dose 
frequency and duration of drug administration 
J) timing of termination of experiments 
k) technique of reading blood films. 
These factors were controlled, as far as possible 
during drug tests. In addition it was found necessary 
to standardise the age of infection of the donor mouse 
- a four day infection being used. 
In all the drug tests undertaken,, particular care 
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the bleeding of the donor nice and inoculating the 
recipients; b) the time interval between the inoculation 
of parasites and the first injection of drug; c) the 
randomising of the mice by weight throughout the exper-
imental group of mice, and d) the laboratory conditions 
of the experimental mice. The two types of drug test 
employed in this study were as follows: 
(a) The simple suppressive test 
This test was primarily used for the analysis of 
the products derived from crosses carried out between 
parasite lines. The test allowed a line to be class-
ified as either drug-sensitive or drug-resistant. 
The procedure for the test is summarised in Table 
S. From this table it will be seen that the presence 
of parasites in the blood of drug treated and undrugged 
mice on day four resulted in the parasite line being 
classified as drug-resistant, whereas if only the two 
mice which did not receive drug treatment exhibited 
paraeitaemia on day four, the line was described as 
drug-sensitive. 
Lb) The modified Warhuret bioassay 
The Warhuret bioassay (Warhuret & Foiwell, 1968) 
is a complicated test requiring the use of a number of 
parasite inocula of different sizes. 	Peters (1968a), 
described a simpler form of the bioassay involving one 
size of inoculum, which is only valid if all the 
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parasite lines being compared for their response to a 
drug grow at equal rates during the test period, both 
in the presence and absence of the drug. 
The test measures the effect of a single injec- 
tion of the drug on the time interval between inocul- 
ation of blood parasites into a mouse and the presence 
of a certain level of erythrocyte invasion in the mouse. 
This time interval is here termed the "test period". 
As this study included P.b.yoelii lines, the end-point 
was taken as a 1% parasitaemia. At this point in a 
blood infection of P.b.yoelii growth is still exponential. 
The procedure followed for testing one parasite 
line was to inoculate 4-6 week old C57 or T.O. mice 
with 1o6 parasites. After three hours, each mouse 
received an injection of drug or injecting medium. Each 
dose of drug was given to 4 mice. Blood smears were 
prepared daily for each mouse, commencing 24 hours after 
the drug injection, and these were terminated after a 
1% parasitaemia was recorded for each mouse. The course 
of infection in each mouse was examined by plotting the 
log % parasitaemia against the day post inoculuin. The 
average duration of the "test period" was calculated 
for each group of mice receiving a different drug treatment. 
So that tests carried out on separate occasions 
could be directly compared, the effect of the drug treat- 
ment was also expressed as the increase in the length 
of the "test period". This increase was calculated by 
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subtracting the average length of the "test period" 
recorded for the mice not receiving the drug from the 
average duration of the "test period" recorded for a 
group of mice receiving a certain dose of drug. 
Drug doses used 
pyrimethaaiine - At the beginning of the research, 
trials were carried out using various drug doses. Even-
tually drug treatments of 2 and 50 mg/kgm were selected 
as the most suitable, because 2 açj/kgza was found to be 
sufficient to delay the drug sensitive parasite lines, 
17X 9 N67 and 33X in reaching a 176 parasitaemia, whereas 
50 mg/kgm was found to affect the time taken by the 
selected 'resistant' lines in reaching the end point. 
At a later date a 75 or 100 mg/kgm dose level was intro-
duced as it was hoped that these larger doses would 
differentiate between the levels of resistance exhibited 
by the 6 pyrimethamine-resistant lines obtained by 
selection. All drug treatments in these tests were given 
by the oral route. 
Suiphadiazine - As a range of 3 drug doses with 
the dified Warhurst Test proved to be successful with 
pyrimethamine, it was decided to use the same procedure 
with sulphadiazine drug tests. It was not considered 
necessary to prepare a dose response curve for this 
drug as the most suitable highest drug dose was known 
to be one which delayed the growth of the parasite 
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inoculuau in reaching a 1% par asitaemia, but did not 
delay it to such an extent that the iune responses 
of the host would be brought into action and affect the 
growth rate of the parasites. The first tests using 
50()ag/kgm as the highest drug treatment recorded delays 
of between one and five days for different parasite 
lines and therefore suggested that this dose was suff-
icient to distinguish between the responses of the 
parasite lines to suiphadiazine. the other drug treat-
ments given were 25 and 125 ag/kgm. 
(11) Starch gel electrophoresis for enzyme 
The presence of glucose phosphate isomerase var-
iants in blood masites was detected by starch gel 
electrophoresis as described by Carter (1970). Para-
sitised blood was collected from rodents by bleeding 
from the brachial vessels into citrate saline. 	After 
centrifugation at 19000 g for five minutes, the upper 
brown layer of parasitised cells was removed and freeze-
dried to break up the parasites. For electrophoresis, 
2 mg of freeze-dried material was dissolved in 0.02 mis 
of distilled water. Filter paper strips were soaked 
in the extract samples for insertion into the gel. 
The gel buffer was 0.01M Iris HC1 pH8.0 and the 
electrode buffer 0.03M Iris HC]. pH 8.0. The regions 
of enzyme activity were made visible by linking the 
reaction to the reduction of the dye MIT tetrazolium, 
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which formed an insoluble blue deposit. On this system, 
the parasite CIPI enzymes could be clearly distinguished 
from host blood enzymes, as the former moved towards the 
anode, while the latter moved in the cathodal direction. 
(3.2) The test of PAM requirement for growth of para-
site lines. 
A simple test was adopted. Parasites were harvested 
from mice maintained on the normal 0.059 PAM water 
supplement. 106  par asi tee were inoculated into 8 male 
T.O. weanlings. Four of the mice were being maintained 
with the 0.05% PAM supplement, while the remaining 
mice had never been given PAM. 
On day 4 post-inoculuin, individual blood smears were 
taken and the ratio of mean parasitaemias of the two 
groups of four mice determined. This ratio was used 
as the measure of the PAM requirement for growth of 
the parasite line. 
(13) The classification of the parasite line according 
to the development site in the rodent host. 
The parasite lines could be distinguished by their 
development in different types of erythrocytes. Two 
classes of line were observed: a) those which mainly 
developed in reticulocytes, termed 'R' lines, and b) 
those which developed in both mature erythrocytes and 
reticulocytes, termed 'N & R' lines. 
At low parasitaernias, Giemea-stained blood-smears 
of both classes of parasite line appeared identical. It 
was customary, therefore, to wait until a 10% parasit-
aemia was present before describing the development 
site of a line. 
The classification of development site of a para-
site line was carried out with T.O. or C57 mice which 
had been injected with 106  parasites. 
(14) Genetics 
Only the results obtained with one cross are reported 
in detail. The procedure for conducting and analysing 
the cross was undertaken in five stages: a) conducting 
the cross and recovering the products of the cross; b) 
testing for reassortment of the parental characters 
among the products; C) cloning the products; d) 
characterisation of the cloned products and (e) control 
studies. 
Details of the procedure adopted for each stage 
(a) Condectin9 the cross and recoveriB2 the products 
The general method for conducting a cross has 
been reported elsewhere (Walliker et a].., 1971 and 1973) 
and is summarised in Figs 2 and 3. Groups of rodents 
were inoculated with one of the two parasite lines. On 
the fourth day post-inoculum, the rodent infections were 
examined for exflagel lation and the number of exf lag-
ellating bodies observed per microscope field recorded, 
wo rodents, one infected with each parasite line, were 
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Fig. 3 	The procedure adopted for the analysis 
of the products of a cross 
Stabilate of 
blood infected with the 
products of the cross 
stored in.p freeze 
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T)r :'(LC t:, of 
iudiviau.,? clnes 
individual clones for :- 
(I) GPI enzynxe type 
response to pyrimethaid.ne  
effect of PABA on growth 
development site 
chosen whose infection sIwed approximately equal 
exf]agellation counts. 
The rodents were bled using heparin to prevent 
clotting (5 iu/al blood). The blood was mixed and 
inoculated intravenously into an uninfected rodent. An 
immediate patent parasitaemia was produced. The rodent 
was placed in a cage of mosquitoes. 
After 5 days, the mosquitoes were examined for 
oocysts. Sporozoites were harvested an the thirteenth 
day and inoculated into thicket rats. Patent blood 
infections were normally observed in these rats 4-8 days 
after sporozoite inoculation. A sample of this infected 
blood was stored in liquid nitrogen. 
(b) Testing to demonstrate reassortment of the parental 
characters among the products of a cross. 
A simple suppressive drug test was carried out on 
the uncloned products of the cross between pyrimethamine-
sensitive and resistant lines. A daily drug dose of 
15 mg/kg= pyrimethamne was given. On the fourth day 
post-inoculuia, all the mice were sacrificed and their 
blood individually analysed for enzyme type (p. 36 ) 
The object of this test was to see if the GPI type 
originally associated with the pyrime thamine-sensitive 
parental parasite line was present among the products 
of the cross surviving the drug treatment. 
Parallel simple suppressive tests were carried out 
on pure line parasite material, to ensure that the drug 
regime used would eliminate only the pyrimethamine- 
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sensitive parasites. 
j) Cloning. of the products of a cross. 
Cloning was carried out by dilution, using the 
method described in a previous section (p. 23 ). 
(d) Charactexisatin of PS coned products 
The puss lines involved in the cross described in 
detail, in this study, differed in four characters, 
namely: (i) (WI type; (ii) response to pyrinethamins; 
(iii) the effect of PAM on growth, and (iv) development 
sit.. 
The clones derived from the products of the cross 
were analysed with respect to these characters. This 
was carried out using the tests devised to study the 
pure line parasites, except that in the case of (iii) 
only 3 mice were assigned to each PAM level. 
J46j, Control studies 
The parasite lines involved in the cross were con-
comitantly mosquito passaged with the blood-mixture 
infection. Thereafter the pure line parasite material 
received the same treatment as the products of the 
cross. 
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22 151BY - 45 1j' 106  6 100(s - 
23 - 23 i6 o8  8 100(s) - 
*the route of administration of the drug is indicated by the following: 




Section I : The development of 
lines of P.b.yoelji and P. arçhei  nigertensis. 
- _---p 
Variations in the procedure ot the 
The four strains of pyrinsthamine-sensitive plasmodia 
used in this study were, P.b.yoeiii 17X, 33X and 1511W, 
and P.berghei njgeriensis N67 strain. 
In a number of experiments the parasite material 
received special treatment before drug selection. In 
six experiments the parasite material had previously 
been cloned. In three experiments the parasites were 
subjected to U.V. irradiations several days prior to 
the start of the drug injections. 
In most experiments a daily drug dose of 100 or 
50 ag/kga of pyr Lam the Mifl$ was given, by the oral route. 
Presentation of results of the selectioneejefl$ 
Parasites surviving the drug selection pressure 
were tested by the simple suppressive drug test. The 
line was termed resistant if the drug test showed it to 
be note resistant to pyrinethamine than the sensitive 
line from which it was derived. 
Table ó lists all the single-step selection experi.. 
men ts which were undertaken. 
In studies of drug resistance in bacteria, yeast 
and free-living protozoa, calculations of the frequency 
45. 
with which resistance to a particular drug arises have 
been carried out. 	To determine whether it is valuable 
to calculate such parameters for blood-form malaria 
parasites, the results of experiments in this study which em-
ployed 50 mg/kgm drug dose have been retabulated to 
compare the numbers of resistant lines to emerge in rel-
ation to the following: (i) the number of parasites 
originally inoculated into the mice (Table 7), and (ii) 
the mean number of parasites present per mouse at the 
time of the first drug injection (Table 8). 	In Tables 
7 and 8 the selection experiments have been grouped 
according to the treatment of the parasite material, namely, 
untreated, cloned or U.V. irradiated. 
The characteristics of the selection experiments yielding 
resistant lines 
Of the four parasite strains used in this study, 
three developed resistance to pyrimethamine. These were 
strains 17X, 33X and N67. 
Six separate pyrimethamine-.resistant lines were 
obtained. Two of these resistant lines, 17X(Prl) and 
N67(Pr2) were derived from untreated parasite material, 
while another two, 17X(Pr5) and N67(Pr6) were obtained 
from cloned parasite material. 	The remaining two lines, 
33X(Pr3) and 33X(Pr4) were derived from U.V. irradiated 
parasite material. 
46. 
rh1p 7 	The .ateaxe t 
lines in re]aint 	number of parasites injected 
into each mouse. 
(the figures in brackets are the number of resistant 
lines which were obtained] 
Treatment of Exp. Sensitive The number of mice mac- 
parasite 	No. parasite uiated with io, 1u7  jr 
material 108 parasites 
106 	107 	108 
-----.-- 	 - 
Untreated 10 17X 23(1) 
it 11 of 30(0) 
of 18 33X 18(0) 
TOTAL 30(0) 43(1) 
Cloned 6 N67 30(1) 
U 7 U 10(0) 
U 13 17X 500) 
it 14 19(1) 
to 15 57(0) 
of 21 33X 50(0) 
TOTAL 
- --- .-.- 1-------_----------------------.-.__ 
222(2) 
UVirradiated 12 17X 
-_-_ -- 	-- 
30(0) 
-- 
to 19 33X 17(0) 
it 
- 	 - - - -f-atr---- 
20 30(2) 
TOTAL. 





Table 3 The appearance ofprimetmine-reSiStaflt lines 
,n relation to the mean number of parasites present per 
mouse at the time of the first drug injection. 
[The figures in brackets are the number of resistant 
lines which were obtained] 
Treatment of Sxp. Sensitive The number of mice Total o. ó1 
parasite 	No. parasite with 107,108 or 109 parasites of 
material strain 	parasites present at each type of 
the time of the 1st parasite mat- 
drug injection 	erial subjec- 
7 	8 	9 
tcdtodrug 
10 10 10 treatment 
.1•.•--.!.. 	
- - - 
Untreated 	10 	17X 	 25(1) 
tv 	 11 It30(0) 
of 	 18 	33X 	 18(0) 
TOTAL 	 30(0) 	43(1) --_43.3x109 (1) 
Cloned 	 6 	N67 	 30(1) 
it 7 11 16(0) 
It 	 13 	17X 	 50(0) 
	
14 is 19(1) 
15 	it 	 57(0) 
21 33X 50(0) 
TOTAL 	 107(0)115(2) 125.7x1O(2) 
UV irradiated 12 	17X 30(0) 
of 	 19 33X 	 17(0) 
of 	 20 	it 30(2) 
TOTAL 	 30(0) 	47(2) 47.3x10(2) 
48. 
The frequency of development of pyrimethamine-resistance 
Tables 7 and 8 both contain all the experiments 
carried out with a selection pressure of 50 mg/Icgm of 
pyrimethamine. Table 7 shows that there is some degree 
of relationship between the number of parasites inocul-
ated into each mouse and the number of emerging 
pyrimethainine-resistant lines. However, a strongercorr-
elation can be seen in Table 8, between the size of the  
parasite population at the time of the first drug injection 
and the number of emerging resistant lines. 
In Table 8 the number of parasites, of the four mal-
anal strains studied, which were present at the time of 
the first drug injection have been summated. This summation 
gives the following as the frequency of development of 
resistance: one resistant line per 4.3 x 10 10 untreated 
parasites subjected to drug treatment; and one resistant 
line per 6.3 x 1010 cloned parasites subjected to drug treat-
ment,arid one resistant line per 2.4 x 1010  U.V. irradiated 
parasites subjected to drug treatment. 
Table 5 shows that a total of 6,8 x 10 untreated 
parasites of strain 1511W were present at the time of 
the first drug injections, that is only one sixth of the 
number of parasites of the other 3 parasite strains studied 
which yielded one resistant line. The cause of the 
failure of 1511W to yield a resistant line will be 
discussed in a later section. 
A U.V. dose-response curve was constructed to give 
background information on the effect of this treatment 








Fig .4. U.V. dose-response Curve 
Graph of mean time to reach 1% parasitaemia against U.V. 
dose. S.E. = standard error. 
(Each result derived from 4 infections in T.O. mice).  
Mean Time taken in 
reaching a 1% parasitaemia ± 2 S.E. (days) 
U.V. dose (x 1000 ergs/inm2) 
50. 
on parasite viability (fi.4). Parasites of strain 33X 
were used for this sty. From fig.4 it will be seen 
the large doses of U.V. would appear to affect parasite 
viability as measured with the modified Warhuret bio-
assay, i.e. the calculation of the percentage of para-
sites surviving a given U.V. dose was obtained by cal-
culating the ratio of the mean length of time between 
inoculation of parasites and the presence of a 1% para-
sitaemia for a group of mice receiving zero U.V. and 
of those mice receiving a particular level of U.V. 
treatment. Such a method of calculation assumes that 
the time taken by the infection to reach a 1% parasit-
aemia is directly proportional to the number of viable 
cells originally inoculated, and that the growth rate 
of parasites receiving zero or other doses of U.V. 
irradiations are the same. 
51. 
Section II. The characterisation of pyrimethamine-
resistant and sensitive lines 
This section contains the results of the tests carried 
out on both pyrimethamine-resistant and sensitive lines 
to characterise their response to pyrimethamine and their 
GPI type. The results obtained with the simple tests 
devised to study the suspected variation among the para-
site lines for some additional characters are also 
included. These additional characters were firstly the 
development site, secondly the effect of PABA on growth, 
and finally the response to suiphadiazine. 
(a) Response to pyrimethamine 
This study was undertaken to compare the response 
to pyrimethamine of the three drug-sensitive strains; 17X, 
33X and N67, and the six drug-resistant lines obtained 
by selection. 
The modified Warhurst bioassay was used in this study 
with an end-point parasitaeauia of l (see p.  33). 	It 
will be recalled that the 'test period' is the interval 
between parasite inoculation and the recording of a 1% 
parasitaeaia. 
Tables 9a and 9b contain the results of the 37 tests 
carried out in nine experimental groups. Results are 
expressed as the length of the 'test period' observed, 
and the increase in the 'test periods  after drug treat-
ment. The results for individual mice employed in these 
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Fig.5. Response to Pyrithaaine 
Graph of man results of modified Warhurst bioassays 
on 9 parasite lines. All experiments carried out in T.O.aici 
A tabular presentation of these results is given in Table 
23b, Appendix B. 

















2 	 50 75 
log drug dose (ag/kga) 
.56. 
Two strains of mice were used for these tests: C57 
and T.O. mice. A summary of the 'test period' values 
obtained using T.O. mice is given in Fig.5. The methods 
of summation of the results from individual experiments 
and of calculating the accompanying standard errors is 
given in Appendix C. 
Figure 5 indicates that the response of the pyri-
methamine-resistant and sensitive parasite lines to 
pyrimethamine could be clearly distinguished using this 
test. However, it was found to be difficult to use this 
test to distinguish between levels of drug-resistance, 
as the order of increasing resistance of the parasite 
lines to the action of the drug varied with each drug 
dose given. In general, however, the results obtained 
with the 50 and 75 mg/kgm drug doses suggested that P.b. 
yoelii 11X and 33X were more sensitive to the action of 
pyrimethamine than P.b. nigeriensis N67, while the 
pyrimethamine-resistant lines derived from the 33X and 
N67 parasite material appeared to be more strongly 
resistant to pyrimethamine than the two lines obtained from 
the P.b.yoe]ii strain 17X. 
(b) The Stability of resistance of the 6 pyrimethamine 
resistant lines 
Since the development of the six pyrimethamine-
resistant lines by selection, the lines have been main-
tamed in the laboratory by blood and mosquito passage, 
with periods in liquid nitrogen. Some details are 
57. 
given of the individual life histories of these 
lines. 
17X(Prl): This line was developed in June 1970. Init-
ially the level of resistance of this line was followed 
with a 4 day suppressive drug test. During the period 
from June to September 1970, 17X(Prl) underwent 3 mos-
quito and 36 rodent passages, and was kept for 6 rodent 
passages under a low level of drug pressure (5 mg/kga 
administered on day 1 post-inoculum), without change in 
the response of the line to pyrimethamine. The level 
of resistance of this line was subsequently followed 
with a modified Warhurst bioassay. 	Between Octobers 
1970 and 1972, this line underwent 53 rodent passages; 
18 mosquito transmissions; and a S month period in 
liquid nitrogen without any significant reduction in its 
resistance to pyrimethamine. 
N67(Pr2); This line was produced in June 1970. 	It has 
undergone 9 cyclical and 68 blood passages without 
changing its degree of resistance to pyrimethamine. 
Thirteen clones of this line were also tested for resis-
tance to pyrimethamine and all, proved to be as resistant 
to the drug as the original, uncloned line. 
33X(Pr3): Line 33X(Pr3) was produced in June 1971. It has 
undergone 50 rodent passages, 5 mosquito passages, and 
two eight month periods in liquid nitrogen store without 
loss of resistance. A line cloned by dilution has been 
shown to possess the same level of pyrimethamine-resistance 
58. 
as the original uncloned line. 
33Xr4j: This line was developed in June 1971, since 
then it has undergone 26 rodent and 3 mosquito passages 
without loss of resistance. 
17X(Pr5): This line was isolated in November 1971. 
Three attempts to transmit the line through mosquitoes 
were unsuccessful. This lack of success can probably 
be explained by the fact that the line had undergone 15 
blood passages since the previous mosquito transmission. 
The drug resistance of this line has remained stable 
through 15 blood passages. 
N67(Pr6): Line N67(Pr6) was produced in November 1971. 
This line has undergone 2 mosquito and 15 rodent passages 
without change in its level of resistance to pyriinethamine. 
Enzyme type 
Carter (1970) demonstrated that strain 17X could be 
distinguished from 33X and N67 by starch gel electro-
phoresis of the enzyme glucose-phosphate isomerase (GPI). 
The six pyrimethamine-resistant lines obtained in this 
study were found to possess the same GPI type as the 
parent strain from which they were derived (Table 14). 
Development site 
The parasite lines were classified as either; R, 
developing mainly in reticulocytes; or M & R. developing 
in both mature and immature erythrocytes. The appearance 
59. 
of blood infections from these types of development can 
be seen in Figs ôa and 6b. 
A survey carried out in four T.O. mice per parasite 
line in August 1972, showed the development site of the 
parasite lines to be as follows:.. 
R: 	17X 9 33X9 17X(Prl) and 33X(Pr4). 
M & R: N67 0 N67(Pr2) 0 33X(Pr3) 0 17X(Pr5) and N67(Pr6). 
On other occasions, the development site associated with 
a given line was usually found to be the same as that 
listed above, however occasionally a line normally of 
the R type was found to be extensively inhabiting mature 
erythrocytes. This change in development site was 
associated with parasite material which had undergone 
more than 12 blood passages. 	17X(PrS), is a line which 
had changed its development site type: when this line 
was produced in 1971 it was an R type. 
(e) The effect of PABA on growth 
A comparison was made of the growth of each parasite 
line in two groups of "clean" mice, one group being 
maintained on a diet supplemented with a 0.05% solution 
of PAM in the drinking water (the standard mouse diet 
used in the laboratory), while the other group did not 
receive a PAM supplement at any time prior to the 
parasite inoculations or during the course of the infections. 












Fi2.6. The development site characteristics of 
Pb. yoelii lines. 
Blood pictures on day 4 post-inoculum of infections 
initiated with an inoculum size of 10  parasites. 
Fig. ba. R development site, that is development 
restricted to reticulocytes, of line 33X. 
The parasitaemia in this type of infection follows 
the reticulocyte numbers in the blood, therefore, the 
rise of parasitaemia is slow and is dependent upon the 
reticulocyte response of the host to red blood cell 
destruction. This type of infection is not lethal. 
Fig. 6b. M&R development site, that is development 
in both mature and immature erythrocytes, of line 33X- 
(Pr3). 	This infection type mainly inhabits reticulo- 
cytes when blood infection levels are low, but soon 
after becoming patent the parasites also invade mature 
erythrocytes, and thereafter parasitaemias rise steadily 
until 80% or more of the red blood cells are infected 
and the mouse host is severely anaemic. 
Fig. 6c. Uninfected blood. Reticulocytes may be 
identified by their large size and strong blue stain-
ing with Giemsa's stain. 
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Mean parasitaemia day 4 post-inoculum without PAM LOO 
Mean parasitaemia day 4 post-inoculum with a 0.059 
PABA supplement 
Table 10 lists the values of this ratio obtained 
in one experiment in T.0. mice. It will be realised 
that a ratio of the order of 100% would indicate that 
the line under study grew equally well up to day 4 post-
inoculum in mice not receiving the MBA supplement as 
it did in the mice receiving the MBA supplement i.e. 
the parasite line was not dependent on the PAM supple-
merit for its rate of growth, whereas a ratio very close 
to zero would indicate that the parasite line grew very 
poorly in mice not receiving PAM as compared with its 
performance in mice receiving the PAM supplement and 
therefore suggests that this parasite line is heavily 
dependent on the PABA supplement for its growth. 
A comparison of the values of this ratio obtained 
in one experiment which tested 9 parasite lines on one 
occasion (Table 10) reveals that all 9 parasite lines 
tested experienced a slower rate of growth in mice not 
receiving the PAM supplement, compared with their 
growth rate in mice receiving PAM. However, their rates 
of growth were not equally reduced by the absence of the 
PAM supplement, as is demonstrated by the ratios listed 
in Table 10. The mean parasitaemia on day 4 post-
inoculum of line 33X(Pr3) was only about 50% in the mice 
not receiving the PAM supplement of the mean parasit-
aemia in mice receiving the PAM supplement, whereas 
63. 
Table 10, The Effect of PAM on the growthof9parasit. 
lines: A comparison of the parasite growth (as estimated 
by mean parasitasnia day 4 poe t-inoculu) in 2 groups 
of nice, 1 group being maintained with a PAM Supplement 
in their drinking water. 
- 
Parasite Addition to 	Mean % parasitaeaia 
line 	mouse drink- of 4 T.O. mice on 	Ratio' 
ing water 	day 4 + SE 
17X PAM 4.5 + 0.61 
NONE 0.5; 0.16  11.1% 
17.(Pr1) PAM 5.7 + 0.96 
NONE 0.0 + 0.00 
17X(Pr3) PAM 9.6 + 234 
NONE 0.9 7 0.65 9.4% 
N67 PAM 441 + 8.48 
NONE 2.0 1.84 4.5% 
N67(Pr2) MBA 36.5 + 2.40 
NONE 3.77 2.05 10.1% 
N67(Pr6) PAM 54.0 + 4.67 
NONE 1.5 1.32 2.8% 
33X MBA 3.3 + 1.10 
NONE 0.5 0.52 9.1% 
33X(Pr3) PAM 23.3 + 2.69 
NONE 13.5 + 4.07 3799 
33X(Pr4) PAM 9.5 + 1.34 
NONE 02 0.45 2.1% 
'Ratio a Mean parasitaemia day 4 post-inoculua& 
without PAM x 100 - 
Mean paraiitaeaia day 4 pot-iicu1un 
with a 0.05% PAM supplement 
64. 
the other parasite lines tested all experienced mean para-
sitaemias in mice not receiving PABA of between 09 and 
11% of the mean parasitaemia in mice receiving the 
supplement. 
On no other occasion were all the parasite lines 
tested simultaneously. From these results it was consid-
ered that line 33X(Pr3) might be in some way less dependent 
on a PAM supplement for its growth. 
It was decided to examine a series of clones of this 
line for their dependence on PABA for growth, with a view 
to studying the genetics of this character. These results 
are included in a later section (page 78). 
It was concluded that the capacity of line 33X(Pr3) 
for growth without PABA supplementation could not be 
directly related to the ability of the line to develop in 
mature erythrocytes, for lines N67, N67(Pr2) and 17X(Pr5) 
which all develop in mature erythrocytes, were found to 
have very limited growth in mice not receiving the PAM 
supplement. 
When the effect of PAM on the growth of a resistant 
line was compared with its effect on the parasite strain 
from which it was derived, only 17X(Prl) was found to 
require more PAM for growth than its parental line, 17X. 
33X(Pr3) required less PAM for growth than 33X. The 
remaining resistant lines did not differ significantly 
in their requirements for PAM from the lines from which 
they were derived. 
From these results 33X(Pr3) was classified as of 
low dependence on PAM for growth, while the remaining 
63. 
8 lines which had been studied were classified as highly 
dependent on PABA for growth. 
(f) The response to Sulphadiazine 
Suiphadiazine is antagonised by PAM. When plas-
modia blood infections in mice maintained on a 0.05% 
PAM drinking-water supplement were treated with high 
doses of suiphadiazine (200 mg/kgm) on day 0 post-inoculum, 
the subsequent parasite growth was the same as control 
parasite infections which had not received the drug 
treatment. It was therefore decided to reduce the PAM 
supplement to a tenth of the usual level i.e. a 0.005% 
solution. 
Initial studies suggested that this lower level of 
PAM supplement allowed the same rate of parasite growth 
to a 1% parasitaemia end point as the usual 0.05% level. 
A comparison of the time taken by parasite infections 
to reach a 1% parasitaemia in C57 mice whose diet was 
supplemented with either a 0.05% or a 0.005% solution of 
PAM has been carried out using Students 't' test (see 
Appendix C)  The results for this exercise being the growth 
rates of the "control" groups of mice in the modified 
Warhurst drug tests which did not receive treatment 
with pyrimethamine or sulphadiazine (see tables 230_and 25), 
in which all infections were initiated with an estimated 
106 parasites. 
Two "t" tests were carried out. In the first, the 
two samples to be compared were compiled solely on the 
basis of the PAM supplement which they received, and 
both samples contained infections of a number of diff-
erent parasite 1jns. The means of these two samples 
in reaching a 1% parasitaemia were 2.4 days (for the 
0.05% supplement sample, sample size 32) and 3.0 days 
(for the 0.005% PAM supplement sample, sample size 72). 
The t value obtained for this test suggests that the 
difference between the sample means was too large to be 
due to chance alone (p = 1%). 
In the second test, only the results of infections 
with strain 17X(Prl) were assigned to the two samples, 
however the two sample sizes were smaller, namely 12 
mice per sample, than in the first test. The t value 
for this test suggested that the difference of 0.9 days 
observed between the two sample means (0.05% PAM 
supplement sample mean was 2.3 days, while the 0.005% 
PAM supplement sample mean was 3.2 days) was not sig-
nificant (p = 10%) with the smaller sample sizes. 
Tables ii, 12 and 25 (Appendix B) reveal the extent 
of the variation in results obtained with the sulphad-
iazine drug tests. The summation of the results from 
individual experiments on parasite lines has been 
included in tabular form (table 12) as the size of the 
standard errors attached to the mean results does not 
facilitate their graphical presentation, as was poss-
ible with the results of the pyrimethaiuine drug tests. 
An addition tabulation included on the results 
of the su]phadiazine drug tests ranks the results for 
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each parasite line in order of apparent increased res-
istance to suiphadiazine (table 13). This tabulation 
was carried out to determine whether a relationship 
existed between the drug test results obtained and some 
unknown factor varying consistently with time. Table 
13 does suggest that the parasite lines did appear to 
be associated with increasing drug resistance (or 
conversely decreasing drug activity) over the period 
from February to August 1972 during which the tests were 
conducted. 
From table 12 it will be seen that line 33X(Pr3) 
was the least affected by the sulphadiazine drug treat-
ment, in that drug doses of 125 and 500 mg/kgzn with 
infections of this line resulted in much smaller delays 
in reaching the 1% endpoint than with the other para-
site lines studied. 
In conclusion, therefore, despite the large var-
iation in drug test results obtained, it was considered 
that line 33X(Pr3) was more resistant to suiphadiazine 
than the remaining 8 parasite lines studied. In a later 
section a discussion will be included of other factors 
which might have affected the results obtained with this 
drug, and caused the variation in results observed in 
repeat experiments on the same parasite line. 
Table 13, Rankinc 0* results obtained 4xom individual 
experiments on each parasite line in order of increas1PQ, 
resistance to su lphadiaains indicated by the.sults. 
- 
Parasite 	Experiments listed in order of mores.- 
Line 	 ing resistance to su1p*adiasine as 
measured by 	mean results in each 
- .xperiasnt. 
1IX 3 3 	6 
1467 3 4 
33* 
17X(Prl) 2 1 	6 
1467(Pr2) 3 4 
33X(Pr3) 3 1 	4 
33X(Pr4) 5 
IIX(PrS) 6 
N67(Pr6) 3 4 
Footnotes 
2.. Experiments carried out between February and August 1972. 







3. This ranking found for only 2 of On 3 dug doses, namely 
25 and 135 ag/kgm, at 500 ag/kga experiment 3 suggested line 
33X to be more resistant to sulphadiaziaa than the result 
obtained in 2xperiment S. 
70. 
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The results of these investigations to character-
ise the 9 parasite lines in this study are summarised 
in Table 14. 
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SECTION III : GENETICS 
Preconditions for successful crosses 
A precondition for successful crosses in this 
study was found to be the use of two parasite lines 
with the ability to induce very heavy mosquito 
infections. This ability is enhanced by repeated 
mosquito transmission and declines immediately after 
cloning. As genetically uniform material is 
required for crossing experiments, the newly cloned 
parasite lines should undergo 3 or 4 successive 
mosquito transmissions before a cross is set up. 
Analysis of a cross between line 17X and line 33X(Pr3) 
Line 17X is GPI-1 and pyrimethamine-sensitive. 
Line 33X(Pr3) is GPI-2 and pyrinethamine-resistant. 
In addition, 17X develops mainly in reticulocytes and 
has a strong dependency on PAM for growth, whereas 
33X(Pr3) can develop in both mature and immature 
erythrocytes and is of low dependency on PAM for 
growth. Line 33X(Pr3) probably acquired its PAlM 
dependency and development site characteristics at 
the same time as resistance to pyrimethamine. 
The procedure followed for conducting the cross 
and recovering the products is given in Fig.?. 
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A iPX-type analysis of the blood inectiun of thicket 
rat 272 A4C showed equal proportions of GPI-] and 2 
parasites among the products of the cross. 
The results of the test to indicate whether 
recombination of the parasite lines had occurred, are 
set out in Table 15. These suggested the presence of 
parasites with a recombinant combination of characters, 
namely. GPI-1 and pyrimethamine-resistant, among the 
products of the cross. 
Table 15.Results of the simple suppressive tests 
carried out on parasites from Stabilates 3324 316 and 333 
Infection Parasite Mouse Pyrimeth- Parasites GPI-type 
derived line 	No. 	amine 	present of para-. 
from 	 treated day 4 	sites present 
Stabilate 	 post- on day 4 post 
No, 	 inoculum -inoculum 
332 	17X 1-2 YES NO - 
3.4 NO YES 1 
333 	3X(Pr3) 9-10 YES YES 2 
11-12 NO YES 2 
316 	Products 5-6 YES YES 1&2 
of the 7-8 NO YES 1&2 
cross 
Forty clones were derived from the products o 
the cross, these are termed the product clones, and 20 
from each of the pure lines. All these clones were 
successively characterised for GPI-type s response to 
7'.  
pyrimethaijne and development site. Twenty-seven 
of the product clones and all of the pure line clones 
were examined for their degree of dependency on PAM 
for growth. 
The GPI-type and pYrimethamine..ri.p,nse chara-
cteristics of all the clones are recorded in Table 1. 
Table 16: Characteristics of Clones for GPI-type and 
responseto pyriaethazujne 
Sent = pyrimethaajne.s.nsjtjv. 
Re. u pyriiaethamjne.resjstant 
Origin of No. of 	
o Classes f Parasite:- 
clone 	clones GPI-1 GPI-1 GPI-2 GPI-2 
isolated Seas Res Seas Res 
17x 	 21) 	20 




0 	14 3 	23 
The 40 product clones consisted of 23 clones with the 
Parental combinations of these characters and 17 
recombinant clones. However, no product clones of 
the 17X parental combination, that is GPI-1 and pyri-
sethamine-sensitive s  were obtained. Many more GPI-1, 
pyriaethamj.,j5 tant recombinant parasites were among 
the cloned products than the GPI-2, pyriaetham.t... 
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sensitive class of recombinant parasites. 
The clones derived from the two pure parasite 
lines were associated with the same development site as 
the lines from which they were derived. The develop-
ment sites of the 40 product clones are listed in 
Table i, in conjunction with their GPI type and 
pyrimethamine-response character. 
Table 17: The Development Site of the Clones Studied 
Res = pyrimethamine-resistant 
Sens = pyrimethamine-sensitive 
R 	= develops in reticulocytes 
M&R = develops in mature and immature erythrocytes 
V 	= variable development site, i.e. some infections R, 
others M&R. 
Origin of No of No of clones of each Clones with 
clones clones combination of parental non- 
characters parental 
characters 
-2 _GPI -GPI-1 
Sens Res Sens Res Res 
M&RR 4&R R M&R V  
17X 20 20 
33(.rz3) 20 20 
s s 40 2 9 3 1 23 2 
Pxiducts 
The development site character did not always segregate 
with the pyrimethamine-response character. However, as 
the product clones were predominantly R development site 
and pyrimethazuine-sensitive, or M&R development site 
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and pyrimethaxnine-resistant, there is a suggestion of 
linkage between these two characters. 
The effect of PAM on the growth of the pure line 
and product clones was examined. The method and ratio 
used were the same as those used previously to compare 
the effect of PAM on the growth rates of parasite 
lines and strains (see page 37). 	It will be recalled 
that for each parasite line a comparison was made of 
the growth of the parasite line in two groups of "clean" 
mice, one group being maintained on a diet supplemented 
with a 0.05 solution of P4BA in the drinking water, 
while the other group did not receive a PAM supplement 
at any time prior to the parasite inoculations or 
during the course of the infections. The index used 
to compare the effect of PABA on the growth of each 
cloned parasite line was the following ratio:- 
mean parasitaemia day 4 post-inoculum 
without PAM - 
	 100 mean parasitaemia day 4 post-inoculum 	X 
with a 0.05% PAM supplement 
The results on the effect of MBA on the growth 
Of parasite clones were all obtained in one experiment 
and proved to be complicated. An unexpectedly broad 
range of values for the index ratio was obtained for 
each set of clones (i.e. the 17X pure-line clones; 
33X(Pr3) pure-line clones, and the product clones derived 
from the cross of these two pure lines). However, as 
can be seen from Fig.8, histogram a, the range of the 
ratios obtained for each set of pure line clones did 









Fig.B. Histograms of the effect of PABA on the growth of pure 
line 17X and 33X(Pr3) clones, and on cloned products of a cross 
between these two parasite lines, cross tabulated with other 
characteristics of these clones.'  
Histogram a: Pure line clones - the effect of PABA on the growth of 
pure line clones as measured by Ratio. 
Key to a - 












It will be seen from histogram a that the range of ratio values 
obtained for each set of clones did not overlap, for whereas the 
range of ratios for 17X clones extended from 0% to 20% the range 
for 33X(Pr3) clones was from 30% to 1007a 
The full results of the experiments summarised in Fig.8 are 
included in Tables 27, 28, and 29 in Appendix B. 
Ratio = 	Mean parasitaemia day 4 post-inoculum without PABA 100 
Mean parasitaemia day 4 post-inoculum with a 0.0575 
PABA supplement 
Ratio 
Response to Pyrimethamine 
Number of Clones 
Ratio 	 - 
Development Site 
Number of Clones 
Ratio 
Histograms b, c and d: Product Clones - the effect of PABA on the 
growth of clones derived from the products of a cross, between lines 
17X and 33X(Pr3) as measured by the Ratio2, cross tabulated by:- 
b. GPi-type 





Key to b 
Key to c 
Pyrimethamine-
sensitive 
D Pyrimethamine- resistant 
Key to d 
R development site 
0 M&R development site 
Variable develop- 
ment site 
Histograms b, c and d demonstrate the distribution of ratio values 
obtained for the product clones, i.e. parasite growth without 
PABA measured as a percent.gc of the grcwth on the standard PABA 
diet, separately cross tabulated by the 3 characteristics by which 
the parental lines differed. 	Each product clone is represented 
by a square in the same position in the 3 histograms. It will be 
observec that the 3 characteristics making up the "17X phenotype" 
are representea by Mwhereas the 1133X(Pr3) phenotype" is repres- 
ented byFGj. 	ThUs an examination of the shading pattern of 
histograms b, c and d allows the product clones which exhibited 
a non-parental combination of characteristics to be distinguished. 
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not overlap. 
The distribution of the ratios obtained for the 
product clones (see Fig.8, histogram b) extended from 
0% to 95%,that is the absence of a PAM supplement 
appeared to completely prevent the growth of some clones, 
to have some effect on the growth rates of other clones, 
and to have negligible effects on the growth of others. 
These results of the effect of the PAM supple-
ment on the growth of the product clones were examin-
ed for evidence of linked segregation of GPI-type, 
response to pyrimethamine and development site, (Fig.8, 
histograms b, c and d respectively), but no evidence 
for linked segregation of these characters was found. 
However, of the 40 product clones obtained, only 27 
clones were examined with respect to the effect of 
PAM on their growth, and furthermore the majority of 
the clones not selected were of one class of parasite, 
namely GPI-2, pyrimethamineresjstant and t4&R develop-
ment site. Therefore special care must be taken in 
the interpretation of these results. 
No estimates were made of the standard errors 
attached to the index measuring the dependence of the 
cloned lines on PAM as each mean index value was cal-
culated from parasitaemias recorded in 2 groups each 
containing only 3 mice. The results obtained for all 
the individual mice involved in the experiments are 
however included in Tables 27 - 29 in Appendix B. 
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In summary, therefore, clones of both recombinant 
and parental combinations were obtained from the 
Products of this cross, although one class of a parental 
combination of characters was not represented among the 
product clones. 	The characters believed to have been 
acquired by the 33X(Pr3) line at the same time as 
pyriniethamine-resistance did not always segregate with 
the pyrimetriamine-resistance character. There was 
some evidence of linked segregation between the pyri-
methamine response and development site characters. 
A discussion of the numbers and classes of parasites 
obtained among the product clones will, be included in 
a later section. 
3. Analysis of 7 clones derived from a cross between 
line 17X(Prl) and line N67. 
Line 17X(F'rl) is GPI-1 and pyrimethamine- 
resistant, whereas line N67 is GPI-2 and pyriniethamine-
sensitive. 
This cross was carried out by Mr A.Oxbrow. Details 
of the procedure for conducting the cross and recov-
ering and cloning the products of the cross have been 
described elsewhere (Oicbrow, 1972). 
To examine if more than one level of resistance 
or sensitivity to pyrixnethsmine was present among 
the cloned products of this cross, the response of 7 
product clones to pyrimethamine was examined with the 











Fig.9. Response to Pyrimethamine - Graph of the results of 
nodified Warhurst bioassays on 7 clones derived from the 
products of a cross between lines 17X(Prl) and N67. (Each 
drug treatment was given to 4, mice infected with the same 
clone) 
For the results of individual mice and a tabular presentation 
of the results in this figure, see Tables 26a and 26b,Appendix B. 
Mean increase in the 'test period' ± 2 standard errors 
83. 
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The mean results obtained with this drug test 
are included in Table 18, and summarised in Fig.9. 
Individual mouse results obtained in these drug tests 
are included in Table 26, appendix 8. 
From Fig.9 it will be seen that the drug tests 
carried out on the 7 product clones only distinguished 
one pyrimethamine-resistant and one pyrimethamine-
sensitive group of product lines. 
* w a; 
'-I 
0Inou0t- 








a, a, • . cnai . . . . 
3  
flØ 	.EIQvIQ ? 
p.4 ' 
0 .0 i • • • • • 
(0 
_ uv H00'r-1 
0 0 )4 '.4 
 • • • • 
do 0  
Q4 
'H ('H • 0 ' • • 
0. Nin, 0 0000l00 
U) 
o . . . . . . . 
14 
3; 	.4.1 
•• __ • • , , , • 
'4 in 
a; a; a;'.' C') 
0 0 ,H r.4 4 C' 4 
o 
'4 
4.4 W 3; 	C) 
? ( 
-Q 
H .4.1 J) ,,.4 • • S • • • • 
U + 
r-4 





34 9 04 
a; - 3 • • • • • 
o '.4 'øa, 0 .0 0 a; C.) 




4.1 +J 4J co Int,  - o (0 m . • . • . 
r-4C'r1r-4rlC'1r.4 (0 










.rI 4A 	0 r4 
a; 
o 0r4r4r.4 CC0Cq 4.1 P H •• • • • ' • wcr n cn 
44 44 • • • • • • • U 
(0 +J 4J 4.1 
a; T1H 3, 
H 
0r4 





'40 4) a; 4.1 4.1 
rl 





Before proceeding to a discussion of the genetic 
studies, it is necessary to examine the results obtained 
with the selection experiments for pyriasthamine-
resistance, and the characterisation studies. 
(1) Selection Experiments 
A large number of experimental malaria parasite 
lines have been developed which are resistant to one of 
the standard antifolate drugs used in malaria chemother-
apy, using a selection technique (see Introduction for 
development of proguanil and pyrimethamine-resistance, 
while resistance to cycloguanil has been developed by 
Peters, 1965c; Thompson et al, 1965b; Bishop, 1966a and 
1966b, and Richards, 1966b). 
The most common selection method employed has been 
to subject a parasite line to gradually increasing drug 
pressure over a number of blood passages. For example, 
Bishop and Birkett (1947) obtained a 40 fold increase in 
resistance to proguanil in a line of P.gallinaceum by 
passaging the strain through chicks every 2 or 3 days with 
the largest dose of proguanil which was without effect upon 
the parasites when given over a long period (0.025 mgm/ 
20 ga body weight). After one month the strain was found 
to be able to tolerate higher drug doses and therefore 
the drug dose was gradually increased, until after 4* 
months parasites, which were normal in appearance, were 
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developing in chicks receiving two daily doses each of 
1.0 mgm/20 gin body weight of chick, the largest dose the 
host could tolerate. On the other hand Williamson et 
al (1947), who obtained a proguanil-resistant line of 
P.gallinaceum at the same time as Bishop and Birkett, 
used a selection dose in one of their experiments in the 
region of the maximum tolerated by the host chicks, 
throughout the selection period. An alternative selec-
tion method is to apply selection pressure during only 
one blood passage, as Young (1957), Burgess and Young 
(1959) and Diggens (1970) have shown that resistance to 
pyrimethamine can emerge if a large number of parasites 
are treated with a single period of heavy drug treatment. 
In this study the single session selection method 
was adopted, and altogether 616 infected mice were sub-
jected to 4 doses of between 50 and 200 mg of pyrimethamine 
per kgm body weight, and six drug-resistant lines were 
obtained. These very heavy drug doses were used, as with 
this technique it is essential that no drug-sensitive 
parasites should "break through" the drug treatment. 
Furthermore, as it was intended to use the resistance as 
a genetic marker, it was hoped that this procedure would 
select lines exhibiting only a very high degree of resis-
tance to pyrimethamine compared with the parent line. 
The selection experiments carried out in this 
study were analysed to give a measure of the frequency with 
which pyrimethamine resistant lines emerged. Previously, 
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Rollo (1952a) had reported that resistance to pyrimeth-
amine had developed more rapidly when the drug was given 
during heavy P.berghei infections, while Martin and 
Arnold (1968) established a clear relationship between 
the size of the parasite population at the time of the 
drug treatment and the development of resistance to a 
single dose of pyrimethamine during experiments with 
P.falciparum infections in non-immune volunteers. 
After Coulston and Manwell (1941), Downs (1947), 
and possibly Demidowa (1934) had shown that individual 
blood parasites could be used to initiate blood infect-
ions, Bishop carried out investigations on the frequency 
of development of drug resistance using cloned parasite 
lines produced in this way. In 1958, Bishop reported on 
the development of resistance to metachioridine. By 
carrying out a comparison of the development of resis-
tance in populations of normal parasites and of popul-
ations composed of mixtures of known numbers of resis-
tant and normal parasites, Bishop suggested "that the 
pattern of development of this resistance in normal pop-
ulations could be explained by selections of mutations 
of a frequency of less than 1 in 5 x lO or probably 
less than 1 in lO parasites." 
Bishop (1962), extended this study to include the 
development of resistance to the antifolates, proguanil 
and pyrimethamine. The selection technique used invol-
ved exposing clone-derived material to a series of drug 
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treatments with intervening periods of growth in untreated 
hosts. Bishop reported that the re was some evidence that 
the rate of development of resistance to proguanil 
depended upon the inoculum size used to passage the line, 
although a similar relationship was not found in the 
development of resistance to pyrimethafne. Bishop's 
experiments also showed that high doses of antifolates 
did not prevent the development of drug-resistance as had 
been suggested by Rollo(1952b) and Covell et *1 (1935). 
In order to study the frequency of emergence of 
pyrimethamine-resistance estimates were made in the 
present study of the number of parasites inoculated into 
the host mice at the start of the selection experiments 
and of those present at the time of the first drug 
injection. A relationship was apparent between the 
number of parasites present at the start of the thug 
treatment and the emergence of the resistant lines. No 
difference in the frequency with which resistant lines 
emerged was detected among the parasite populations 
receiving the three selection procedures. However, the 
frequencies obtained were as follows: one resistant line 
per 4.3 x 1010 untreated parasites; one resistant line 
per 6.3 x 1010 parasites derived from cloned material, 
and one resistant line per 2.4 x 10 10 parasites which had 
been subjected to ultraviolet irradiation,. Thus a lower 
incidence of resistance was suggested by this study than 
that obtained by Bishop for metachloridine resistance. 
It is possible however that the use of a single 
session of drug treatment for the selection technique may 
influence the frequency with which resistant lines are 
obtained. For example, this method would not allow highly 
resistant lines to arise through the gradual accumulation 
of heritable changes over a number of generations, and it 
might also allow certain random events to eliminate resist-
ant cells, for example, the newly emerged resistant 
parasites might fail to invade a host erythrocyte or the 
resistant parasite might be destroyed by macrophagic or 
antibody attack. The 6 pyrimethaniine-resistant lines 
obtained in this study were sub-inoculated from fleeting 
patent infections arising after the selection procedure, 
which suggests that the immune responses of the host were 
active at the time the resistant lines emerged, and that 
other resistant lines may have been destroyed before 
producing patent blood infections. 
Of the four parasite strains employed in this study, 
only 151BY failed to yield a resistant line. However, 
fewer parasites of this strain were subjected to drug 
treatment and therefore this failure to obtain a resistant 
line could be due to an inherent inability of this strain 
to develop a resistance to pyrimethamine, or more likely, 
to too small a population of parasite cells being 
subjected to drug pressure. 
Some measure of the frequency with which a drug-
resistant line emerges after selection pressure is useful 
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in determining the origin of the resistance, because the 
us. of selection agents to obtain specific variants 
inevitably obscures the origin of that variant. 	For 
a long time a controversy was maintained concerning the 
adaptation or mutational hypotheses of the origin of 
bacterial variation (Hayes, 1964). Originally, the 
adaptation hypothesis was the more widely held. 	This 
stated that each cell in ,& population had a finite chance 
of reacting to the presence of the selective agent in 
such a way as to become resistant to the action of that 
agent. Gradually, however,, experimental results pointed 
to a mutational origin of variation. The mutational 
hypothesis states that variation arises as a result of 
random, spontaneous events unrelated to the environment 
of the organism and the variants that do arise are 
revealed by the selective agent removing all other types 
of organism present. 	There is now a considerable body 
of evidence showing that stable bacterial variation is 
exclusively due to spontaneous mutation (reviewed by 
Hayes, 1964). One of the most convincing experiments 
revealing the mutational origin of variation in bacterial 
studies was carried out by Lederb.rg & L.ederberg (1952) 
using a replica plating method to isolate streptomycin 
and phage-resistant Eacherichia colt variants without 
directly exposing the bacteria at any tin, to any 
selective agent, thus demonstrating the occurrence of 
spontaneous mutants. 
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This controversy is not however completely 
resolved. Hinshelwood (1946) put forward a further 
adaptationist hypothesis suggesting that contact of 
sensitive bacteria with a drug may shift the normal 
equilibrium of cellular chemical reactions to a new 
equilibrium which is less susceptible to the action of 
the drug. Furthermore, due to the distribution of the 
parent cytoplasm to both daughter cells during binary 
fission, this altered equilibrium could be perpetuated 
for a number of generations. 	No proof of this type 
of adaptation has as yet been found. 	However, there 
is no doubt that certain adaptive mechanisms do occur, 
but the resulting changes in the phenotype produced by 
the influence of a specific environment are not usually 
maintained after the transfer of the variant form to a 
different environment. 	Furthermore, such adaptive 
changes generally occur at a such higher frequency than 
mutational events. 
The methods which have been used to expose the 
mutational basis of variation in bacterial studies are 
not at present available in malarial genetics. However, 
some information is available which strongly suggests 
that pyrimethamine-resistance can arise by mutation. 
Firstly, as mentioned previously, resistance to all of 
the antifolate antimalarial drugs have been shown to be 
stable through blood and mosquito passage, for although 
there have also been reports of pyrimethamine-resistant 
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lines which are labile (Rollo, 1955b, and Bray 1955) 9  
Peters (1970*) has suggested that this apparent lack of 
stability might be the result of a PABA deficiency in the 
diets of the nice used to maintain these lines. In the 
present study all six of the resistant lines obtained by 
selection were found to be stable during blood passage, and 
periods in the deep freeze, while the five lines which 
successfully underwent mosquito transmission also retained 
their resistance through that process. 	Secondly, the 
very low frequency with which resistance lines emerge 
suggests a mutational origin for these variants, as does 
the suddenness with which they are reported to appear 
(Young, 1957; Burgess and Young, 1959; Bishops 1962 1, 
and Diggens, 1970). The ability of cloned parasite lines 
to yield pyrimethamine-resistanoe under selection pressure, 
which was first demonstrated by Bishop (1962) from cloned 
lines obtained in 19580 strongly suggests the mutational 
origin of the resistance. In the present study 2 
pyrimethamineresistant lines were obtained from cloned 
parasite material, one of the clones being obtained by a 
dilution method one month before the selection experiment 
commenced which suggests that the resistant line may have 
arisen during the course of the experiment. 
An attempt was made in this study to employ mutagens 
to increase the frequency with which variant parasite 
types were obtained. Hawking (1966) attempted to use 
mustine to induce cbloroquine-resistance in blood parasites 
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of P.berghei. He injected 5 or 10 rng/kgm of zuustine 
into mice by the intraperitoneal route on the first and 
fifth days post-inocui.um. Chioroquirie was administered 
at a continuous low level in the mouse diet. 	After 
eight months involving 38 passages, there was no resis-
tance and the line was discarded. However, no test 
was carried out to determine whether this chemical was 
mutagenically active to parasites within erythrocytes 
in the doses or route of injection by which it was 
administered. 
Ultraviolet and X-irradiations have been used with 
malaria to produce inactivated sporozoite preparations 
to stimulate the immune response of the parasite's host 
(Mulligan at al, 1941; Russell and Mohan, 1942; Richards, 
1966a, and Nussenzweig et al, 1967). 
An attempt was made in this study to select an 
ultraviolet irradiation dose and administration method 
which could be shown to have some effect on parasite 
development. The preliminary investigation on the effect 
of U.V. irradiations on the viability of the erythro- 
cytic parasites suggested that large doses of U.V. did 
kill blood-form parasites, although the shape of the 
dose-response curve was unusual. The dose-response 
curves of U.V. on organisms able to repair U.V. damage 
generally show a slow decline in viability at low doses 
of U.V. which becomes more rapid as U.V. dose increases. 
This response is interpreted as showing the initial 
efficiency of the repair system breaking down as the 
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it reached the parasite material. 
When the effect of U.V. treatment on the frequency 
of development was investigated it was found that there 
appeared to be little difference in the frequency of dev-
elopment of pyrimethamine-resistance from U.V. treated 
and untreated parasites. The mutants obtained after drug-
selection of U.V. treated parasite material could be a 
mixture of spontaneous and U.V. induced mutants. The 
number obtained would equal x n + y m 	 (1) 
where: x and y are the frequencies of development of 
spontaneous and U.V. induced pyrimethamine-resistant 
mutantsi n is the number of parasites subjected to drug 
pressuxe, and ia, the number of parasites surviving th 
U.V. treatment. 	Due to the delay of 5-8 days between 
inoculation of the U.V. treated parasites and the admin-
istration ol the first drug injection, there were 200 
to 1,000 more parasites present at the time of the first 
drug injection than when the parasites were originally 
inoculated. If the small difference in the frequency 
of development of pyrimethamine-resistance from U.V. 
treated parasites and non-U.V. treated parasites which 
was obtained in this study is substituted into equation 
1, a 36 fold increase in the frequency of development of 
resistance due to the U.V. treatment is found. 	This 
calculation is only included to illustrate how large an 
effect the U.V. treatment must have on the frequency or 
development of resistance before significant differences 
will be observed, in this selection system, between the 
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numbers of resistant lines obtained from untreated and 
U.V. treated parasites. 
The effect of U.V. treatment might be more easily 
demonstrated if the time period between inoculation of 
the parasites and the first administration of the drug, 
which is needed to allow the U.V. induced mutants to 
become manifest, was reduced to 3-4 days. 	It would 
also be possible to enlarge the number of parasites sub-
jected to U.V. in a given experiment, but as it is felt 
that the size of the parasite inoculum should not exceed 
109 so that a large proportion of the inoculated para-
sites contribute to the new blood infection, the selection 
experiment could most usefully be enlarged by injecting 
the parasites into 100-200 mice. 
In the present study two resistant lines were 
obtained from parasites which had been exposed to U.V. 
irradiations. However, as so few resistant lines were 
obtained and as the incidence of resistance appeared very 
similar to that for untreated parasites, it cannot be 
concluded that the lines arose as a direct result of 
the U.V. treatment rather than from spontaneous mutations. 
Despite the limited success of the selection exper- 
iments using U.V. irradiations, an extension of the use 
of mutagens in malaria studies should not be neglected. 
It would be possible to use those mutagens whose mechan-
ism of action is clearly understood, to investigate the 
type of mutational event which gave rise to an altered 
parasite phenotype by carrying out reversion studies. For, 
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example, the mutagenic action of U.V. is known to be 
associated with the production of thymine-dimers in the 
DNA (Wacker et al. 1962). The presence of these diners 
eventually leads to permanent alterations in the genetic 
code due to an error in replication in the portion of 
the DNA containing the diner (reviewed by Deering, 1962 
and Within, 1969). 	Similarly in the field of chemical 
mutagens, it is now known that 5-bromouracil or 2-amino-
purine treatment may result in an A-T base pair in DNA 
being converted to a G-C pairing, and acridine dyes are 
thought to act by the insertion or deletion of a single 
nucleotide causing a frame-shift mutation (Brenner et al., 
1961). 	If a mutagen can revert the altered parasite 
phenotype back to the original parent type from which it 
was derived, it provides information on the original 
genetic change resulting in the altered phenotype. For 
example, a variant whose genetic origin is associated 
with a major alteration in the arrangement of the genetic 
material or with a deletion or addition of a single base 
will not be found to have a high frequency of reversion 
to the original phenotype when treated with base ana-
logues. Such a study would have to be carried out in 
conjunction with genetic studies to distinguish back mut-
ations from suppressor mutations occurring in another 
part of the genome than that which contained the original 
mutation, but would provide insight into the origins 
of parasite variants. 
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(2) Characterisation Studies 
(a) Drug Tests. 
A number of different drug tests were investigated 
during a search for a test which would be sufficiently 
rapid to enable a single researcher to set up and monitor 
the large number of drug tests required for genetic 
work. At one stage a suppressive test based on the type 
devised by Thurston (1950a) was investigated. This test 
allowed a dose-response curve to be produced and follow-
ing the method of Rollo (1952b), an ED50 (the effective 
dose which eliminates 509 of the parasite population) to 
be interpolated from the dose-response curve. However, 
A series of trial tests of this type produced rather 
variable results. Various statistical transformations 
of the results were carried out (including probit analysis) 
with little improvement. Statistical advice was sought 
and Dr W. Hill of the Institute of Animal Genetics 
suggested that insufficient data was obtained in each 
test to construct a satisfactory dose-response curve. He 
suggested that a statistically less suspect approach 
would be to use a fixed drug dose test. Accordingly the 
modified Warhurst drug test (Warhuxst and Folwell,1968 
and Peters 1968b) was selected. 
A 1% parasitaeaia was chosen as the end point of 
this drug test due to the shorter period of exponential 
growth of P.b.yoelii infections compared with P.b.bercjhei 
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N strain infections for which Warhurst and Foiwell (1968) 
had used a 2% parasitaemia as the end point. 	The 
results of this test with pyrimethamine proved success-
ful; the six drug-resistant lines obtained by selection 
could be clearly and repeatedly distinguished from the 
parent parasite lines with this test. However the test 
did not conclusively identify differences in the degree 
of resistance to pyrimethamine exhibited by the pyri- 
methamineresistant lines. 	It is evident from the 
results of selection experiments which employ a gradual 
build up in the strength of drug pressure, that lines do 
exist which possess different degrees of resistance to 
the drug. Diggens (1970) obtained two resistant lines in 
her single session pyrimethamine selection experiments, 
one from a mouse and the other from a hamster infected 
with P.b.berghei strain NK65, which she reported as 
exhibiting similar degrees of resistance to pyrimethamine. 
In the present study there was some indication that the 
lines derived from strain 17X were less resistant to the 
action of pyrimethamine than the lines derived from 33X 
and N67. However it is possible that the selection 
technique adopted resulted in only lines highly resis-
tant to pyrimethamine being obtained. 
The use of the modified Warhurst drug test with 
sulphadiazino was not satisfactory. Variation occurred 
in the results obtained, both within and between experi-
ments, which was considerably larger than that experienced 
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with the pyrimethamine drug tests. One explanation of 
the cause of this large variation could be the presence 
of concomitant infections of Eperythrozoon coccoides or 
Haemobartonella nuns, which have been shown to affect the 
growth of malaria blood infections (Kzetschaar, 1963; 
Peters, 1963 and 1965a; Ott and Stauber, 1967 and Sttngener, 
1968). 	However, examination of blood smears throughout 
the period in which this research was carried out has 
never revealed the presence of such infections. 
An alternative explanation of this large variation 
is related to irregularities in the amount of PAM admin-
istered. 
ui
• Since the early studies of Maier and Riley 
(1942), and Marshall et al (1942), it has become well 
known that the action of sulphonamides on malaria para- 
sites could be antagonised by PAM. 	Hill (1950) and 
Thurston (1950a and 1950b) demonstrated that the antagon-
ism of PAM on the action of sulphadiazine extended to 
P.berghei infections. As the growth rates were erratic 
in groups of mice given identical treatments in single 
drug tests, it is unlikely that the large variation 
recorded in the results was due to
the 
articu1ar combination 
of drug and PAM used. 	Furthermore, Thurston (1954) 
when showing that the antagonism of sulphadiazine by 
PAM was competitive, indicated that a dose of 1.5 mg/kgm 
(given twice daily orally or subcutaneously) antagonised 
0.5mg/kgm of sulphadiazine, but that the dose of PAM had 
to be increased to 50 mg/kgm to inhibit 5.0 mg/kgm of 
the drug. 
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In the present study, the highest dose of sulphad-
iazine used was 500 mg/kgm, while a PAM concentration 
of 0.005% was added to the mouse drinking water. Thurston 
(1954) found that a mouse weighing 20gm drinks about 4 ml 
of waterin 24 hours, of which approximately 3.5 ml is 
taken at night. The mice used in the drug tests in this 
present study also each weighed approximately 20 ga. It 
can be estimated therefore that about 0.2 mg of PAM was 
given daily to each mouse in conjunction with 2, 125 or 
500 mg/kgm of drug. Thus at the highest drug treatments 
the level of PAM is unlikely to have been sufficiently 
large to have strongly affected the action of the drug. 
It may be that the irregularities in PAM between 
mice were sufficient to cause the large variation in 
results obtained. For example, although it is known that 
the solid mouse diet was deficient in PAM, it may also 
have been subject to batch variation. 	Alternatively 
the volume of drinking water consumed by individual 
mice might have varied. The ranking of the results 
in order of apparent increase in drug-resistance did 
suggest that there was an apparent gradual increase in 
the resistance of the strains to sulphadiazine through-
out the period in which the drug tests were conducted. 
This could have been caused by a gradual increase in the 
level of MBA in the mouse diet acting to reduce the 
effectiveness of the drug. "±" tests on the difference 
in the means of the period between inoculation of the 
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parasites and the recording of a 1% parasitaemia in C57 
mice maintained with a 0.059% or a 0.005% concentration 
of PAM in the drinking water of the hosts were carried 
out to see whether such changes in the PAM could affect 
the test results. 	The "t" test carried out on the 
mixed strain results did suggest that the change in 
PAM supplement affected the parasite growth significantly, 
although the "t" test carried out on the difference in 
means of line 17X(Prl) alone did not suggest there was a 
difference in growth rates of this parasite line en the 
two PAM concentrations. 	In addition, other factors 
such as the actual variation in the size of the estim-
ated parasite inocula used to initiate infections might 
have contributed to the size of the difference in the 
means which was obtained. 
Thurston (1954), noted that the action of pyri-
methamine was also antagonised by PAM. However con-
siderably higher doses of the antagonist were required 
to inhibit a certain dose of pyrimethamine than to inhibit 
the same dose of sulphadiazine. Although it cannot be 
ruled out that some factor unrelated to PAPA was the 
cause of the variation in drug test results obtained 
(such as the presence of a further inhibitor, for example 
Hodge and Schneider (1972) found that fructose inhibits 
the action of sulphadiazine on bacterial infections), 
nevertheless the results of the tests on the dependency 
of parasite lines on PAM for growth also suggest that 
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irregularities in the MM of the mouse diet eight have 
been sufficient to affect the .ulphadiazine drug test 
results. Peters (1970b and 1913) has suggested that subtle 
"standard" diet used in his drug test experiments with 
differences in the MM content of the sulphonamides was 
the cause of differences in the results of repeat .xperi'u 
ments. 
The investigation of the dependence of the parasite 
lines on PAM for growth was undertaken because Jacobs 
(1964) had found that a pyrimethamineuresistant line of 
had an increased requirement for PAM as con -
pared with the parent line from which it was derived. 
However in the present study line 33X(Pr3) was found to 
require less MBA for development than the other parasite 
lines, although the growth of line 33X(Pr3) was not 
entirely independent of the presence of the PAM supplement. 
The caparison of the MBA requirements of the two sets of 
clone, derived from 17X and 33X(Pr3) did indicate that 
within each sat of cloned line, there were either parasite 
lines with different requirements for PAM, or more 
probably, that irregularities in the PAM levels of the 
host mice were responsible for some of the variation in 
the results obtained with this test. 
The PAM requirement and suiphadiazine drug tests 
together suggest that line 33X(Pr3) differed from the other 
pyria.thamin...resistant lines. Jaswant Singh et al (1954b) 
suggested that a sulphadiazine'resistant line which was 
indifferent to the presence or absence of MM, might 
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therefore be able to produe its own source of PAM. 
However, the growth of line 33X(Pr3) was not entirely 
independent of the presence or absence of the PAM 
supplement used in this study, but this could be explained 
by the line being able to make or obtain a proportion 
of its PAM from a source not available to the other 
resistant lines. 
To obtain more reliable and repeatable results 
for the response to sulphadiazina and requirement of 
PAM for growth, it would be useful to investigate con-
ducting drug tests in mice fed on a MM-free solid 
diet and given oral injections of PAM supplements, so 
that the PAM content of the diets can be properly  
standardized. 
(b) Development site 
It is well known that for some rodent ira1arias 
invasion of the blood cells is restricted to reticulo-
cytes, that is immature erythrocytes (which appear 
larger and stain a strong blue in Giemsa stained blood 
smears). There is now little doubt that red blood cell 
destruction in malaria infections is in excess of the 
level of parasitaemia, although the cause of this is 
uncertain. Mechanisms such as splenomelagy (George at al, 
1966), osmotic fragility (Fogel et al, 1966), deterior-
ation in erythrocytic membrane function (Dunn, 1969) 
I 
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and autoinzmunization (Zuckerman, 1963 and reviewed 
1969) have been suggested as responsible for the des-
truction of uninfected erythrocytes. The red blood 
cell destruction stimulates the hasmopoistic centres of 
the host and increases the production of the reticulo-
cytes. 
If the parasite line is limited to invasion of 
reticu].ocytes then the size of the parasite population 
is ultimately controlled by the reticulocyte response 
of the host (Ott et al (1967) and Ott (1968)). On the other 
hand, it the parasite line is not limited to development 
within reticulocytes, which generally form only a small 
proportion of the red blood cell population, its growth 
pattern is quite different and it usually reaches a high 
parasitaemia before the immune response of the host is 
sufficiently stimulated to eliminate the infection. 
As the parasite lines in this study could be 
clearly seen to differ in their development site charac-
teristics with consequential effects on virulence, it was 
hoped to use this characteristic as a marker in genetic 
crosses. 
There have been reports of changes in the devel-
opment site of parasite lines in the blood in association 
with the development of other characters. For example, 
Peters (1965d and 1968b) has noted with P.herghei, that 
increase or decrease in resistance to chioroquine is 
associated with a change in virulence. Similarly, 
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Arnold (1967) has reported that the development of 
resistance to chloroquine • pyrinethaaine and sulpbone 
in lines of P,b.rghsi were also accompanied by the lose 
of the ability to invade nature erythrocytes. Arnold 
further noted that certain conditions of the photo-
periodic rythan and endocrine state also affected the 
ability to invade nature erythrocytes. In addition, it 
is well known that the virulence of rodent plasmodia tend 
to increase from that of the original isolate when the 
strain is maintained by repeated blood passage (for 
example s Peters, 1968a). 
In the present study, 17X(Pri), N67(Pr2), 33X(Pr4) 
and N67(Pr6) all retained the development site associated 
with the parasite line from which they were derived by 
se1ection 	lines N67(Pr2) and N67(Pr6) both retaining 
the ability to invade mature erythrocytes unlike the 
pyrimethanine..resistant line reported by Arnold. However, 
33X(Pr3) ocquired the ability to invade nature erythro-
cytes on becoming resistant to pyrinetha*ine although 
33X from which it was derived develops only in reticulo-
cytes, and 1IX(Pr5) although originally restricted to 
reticulocyte invasion, changed after it had failed to 
undergo mosquito passage for a considerable period and 
acquired the ability to invade nature erythrocytes as 
well. 
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(3) Crossing Experiments 
Greenberg and Trembley were the first to attempt 
to cross lines of plasmodia (Greenberg and Trembley, 
195'b and 1954b; Trembley and Greenberg,1954, and Greenberg, 
1956). To conduct a cross with lines of plasmodia it 
is necessary to allow the two lines to undergo cyclical 
passage together. As it is not possible to separate 
micro- and macrogametes, the products of the cross can 
be expected to include the parental phenotypes. 	To 
obtain conclusive proof that hybridization of the two 
parental lines has occurred, it is necessary firstly, 
to identify the presence of non-parental parasite types 
among the products of the cross, and secondly, to 
isolate these new phenotypes to make certain that com-
plementation of the two parental phenotypes is not res-
ponsible for the new parasite type. In addition it is 
necessary to carry out a series of control experiments 
to demonstrate that the new phenotype could not have 
arisen by mutation or by a gene transfer mechanism 
other than hybridization (for example, transduction or 
episomal transfer). 
The crosses reported by Greenberg and Trembley 
which yielded evidence of non-parental phenotypes among 
the products of the cross were between pyriaethamine-
resistant and sensitive lines of P.ga11inaceum. Greenberg 
and Trembley also reported the results of "crosses" 
between lines differing with respect to their growth 
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characteristics (Greenberg and Trembley, 1954atd 
Trembley and Greenberg, 1954), and on a number of 
occasions between lines differing in their response to 
pyrimethamine (Greenberg and Trembley, 1954b and Green-
berg, 1956), where no evidence was obtained of non-
parental phenotypes among the blood parasites arising 
from the joint mosquito passage. 
Trembley and Greenberg (1954) mentioned the 
different gametocyte producing capacities of the parasite 
lines employed in these crosses. During the present 
study a number of unsuccessful "crosses" were also 
carried out, when although both parental parasite pheno-
types emerged from the joint mosquito passage, no 
evidence for hybridization was obtained. From, these 
experiments it was ascertained that a precondition for 
successful crosses was the use of two parasite lines 
which produced very heavy mosquito infections • 	It 
seems likely therefore, that the lack of hybridization 
experienced by Greenberg and Trembley may well have 
been the result of using poor gametocyte producing lines. 
Turning to their more successful cross however, 
Greenberg and Trembley (1954b) carried out a cross 
between P.gallinaceua line M - a benign parasite line 
which was unusual in that it did not produce a secondary 
erythrocytic stage, and a sub-line of line BI which was 
pyrimethamine-resistant and virulent. A combined 
infection of the two lines, initiated with equal numbers 
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of the two types of blood parasites, was passaged twice 
through mosquitoes before the resulting products were 
analysed. The sporozoite induced infections obtained 
after the second joint mosquito passage was found to 
include pyrimethamine-resistant parasites and was assoc-
iated with benign growth characteristics, that is, a 
non-parental phenotype. 
A number of criticism, can be made of the design 
of this experiment. Firstly, the cross was not carried 
out with cloned parasite lines to ensure genetic uni-
formity of the parental parasites. Secondly, the 
mixed blood infection was allowed to develop for five 
days in a chick prior to conducting the cross, by 
which time a parasitaemia of 82% was recorded, and yet 
no control experiments were carried out which examined 
the effect of this joint passage on their growth 
characteristics. The mixed blood infection underwent 
two mosquito passages before analysis of the products 
of the cross was carried out and consequently, 	game- 
tocytes formed in the sporozoite-induced infection 
derived from the first cross (including any hybrid para-
sites) would contribute to the gene pool of the second 
mosquito passage. Finally, Greenberg and Trembley used 
as a genetic marker a growth characteristic which they 
knew to be unstable (Haas at al, 1948; Trembley at al., 
1951, andGreenterg,1956). Gambia (1966) summarised 
the information on these American subs trains of 
P.gallinaceum as follows: 
"when P.Qallinaceua is induced to live under a 
variety of unnatural conditions it seems to change its 
morphology, to lose its capacity to produce gametocytes, 
to produce no malaria pigment in erythrocytic schizonts, 
to develop in haeaopoietic cells and to grow exclusively 
with or without phanerozoites. Probably few of these 
substrains represent true mutations, because after a 
number of normal transmissions, most of them will regain 
the character of the type." 
Thus in Greenberg and Treabley 'a experiment, 
after the two rounds of mosquito passage, when the vir-
ulence associated with the precross mixture had disap-
peared, the presence of pyrimethamina-resistarice with 
benign growth could have arisen by a number of routes: 
1) mutation of the N line confering resistance to pyri-
aetbamine; 2) mutation or physiological change of the 
El line confering benign growth characteristics, 3) 
hybridisation, or 4) another form of gene transfer mech-
anism such as transduction, "synpholia" (i.e. a type of 
episomal transfer) between the parental parasite lines 
(an opportunity for such an exchange occurred during 
Greenberg and Trembley 's experiment during the 5 days 
of joint growth of the parental parasite lines in the 
chick used to initiate the cross). Insufficient controls 
were carried out to determine which of the above alter-
natives had been responsible for the results obtained. 
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Nevertheless, the "apparent transfer of pyrimethaninta  
resistance" reported by Greenberg and Trembley (1954b) 
acted as a guide for later attempts to conduct crosses 
with malaria parasites. 
Reports of crosses employing two of the pyriwethamine-
resistant lines selected during the present study have 
now been published (Walliker et al, 1971 and 1973, and 
Oxbrow, 1972). The additional genetic marker used to 
analyse these crosses was glucose phosphate isomerase(GPI). 
In these experiments care was taken to carry out the 
appropriate control experiments to prove conclusively 
that the non-parental phenotypes obtained with the cross-
ing technique employed, were due to hybridization, and 
not, for example, to an independent mutation arising 
during the crossing experiment among the drug-sensitive 
parasite line, or a gene transfer mechanism other than 
hybridization such as transduction, episomal transfer or 
synpholia. The isolation of a parasite phenotype among 
the products of the cross which is drug sensitive, but 
associated with the (WI type of the drug-resistant parent 
line indicates that mutation is not responsible for the 
appearance of new parasite phenotypes during the cross. 
In addition, the products of the cross were not subjected 
to drug pressure before cloning and therefore the high 
proportion of the new resistant phenotype is unlikely 
to have been the result of an independant mutation. 
Yoeli et al., (1969) reported a gene transfer mechan-
ism between malaria parasites, which they termed 
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synpholia ("together in the nest"), which they suggested 
occurred between 2 parasites developing within the same 
blood cell. Walliker et al., (1973) carried out control 
experiments during the crossing studies to examine 
whether new parasite phenotypes were obtained during 
joint blood and liver development of the two parent para-
site lines employed in the cross. The design of the 
crossing technique was believed not to be conducive for 
synpholia, as high parasitaemias of the joint infections 
did not occur, and no evidence for this phenomenon was 
obtained from the control studies. 
In the present study a third pyrimethamine-
resistant line, 33X(Pr3), was crossed with a pyri-
methamine-sensitive line, 17X, and again non-parental 
phenotypes were discovered among the products of the 
cross. 	The expected and actual ratios of the pheno- 
types among the products of the cross were as follows: 
pyrimethamine- pyrimethamine- pyrimethamine- pyrimeth- 
resistant 	: sensitive 	: resistant 	:amine- 
GPI-1 	 GPI-1 	GPI-2 	sensitive 
GPI-2 expec- 
ted : 	3. 	: 	3 	: 3 	: 1 
actual: 14 : 0 : 23 : 3 
However, it is to be expected that the ratios of 
the different phenotypes among the products of a cross 
between malaria parasites will not be as informative as 
the ratios obtained in crossing experiments with free 
living organisms. 	Only limited control is possible of 
a cross conducted within mosquitoes in which both male 
and female gametes of each parasite line are present. 
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An attempt was made in this study to equalise the 
numb a of exflagellating aicrogametes of each line which 
are contributed to the blood mixture used to initiate 
the cross. 	In addition the sporozoite-induced products 
of the cross were stored in liquid nitrogen as soon as 
they became patent, to prevent distortion of the propor-
tions of the parasite phenotypes among the cross 
products, due to differences in growth rates. However, 
the final proprtions of the parasite phenotypes among 
the product clones might also have depended upon diff-
erences in (i) oocyst and sporozoite maturation rates; 
(ii) the number of sporozoies contributing to the 
sporozoite yield; (iii) sporozoite viability levels, and 
(iv) parasite growth rates in the liver and blood stages 
of the parasite phenotypes. 	In fact lines 17X and 
33X(Pr3) did differ in their growth rates and therefore 
this probably contributed to the deviation of the ratio 
of the phenotypes among the products of the cross. 
Lines 33X(Pr3) and llX also differed with res-
pect to a number of characteristics in addition to their 
response to pyriaethaaine, and their (WI type. 	These 
additional characteristics were, development site and 
dependency on PAM for growth. As was mentioned 
previously (page ioo) the tests devised to analyse these 
characters did not prove entirely satisfactory. Of the 
40 product clones analysed for their development site, 
two proved to have a variable development site, i.e. 
sometimes invading only reticulocytes and sometimes also 
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invading mature erythrocytes. The analysis of the 
characteristics of the product clones suggests that the 
response to pyrimethamine and development site did tend 
to segregate together. However, it also is possible that 
the number of blood passages between conducting the 
cross and analysing the products was sufficiently large 
to affect the development site recorded, for as mentioned 
previously, multi-blood passage of R development site 
lines is associated with the acquisition of the ability 
to invade mature erythrocytes. 
Only 27 of the 40 product clones were analysed 
for their dependency on PAPA for growth. The results 
obtained for this character with the pure line clones 
were more varied than had been expected from the original 
experiment on the uncloned parasite lines. It can be 
argued that the interpretation of these results are beset 
with similar problems as Greenberg and Trenzbley's results 
from crosses utilising growth characters, and demon-
strates again the difficulties encountered with attempt-
ing to use differences in this type of character in 
genetic studies. 
Seven clones derived from the products of a further 
cross, carried out between lines 17X(Prl) and 33X 
were examined for their response to pyrimethamine using 
the modified Warhurst drug test. 	The purpose of 
this examination was to see if the levels of resistance 
of the product clones were different from that of the 
two parent lines. 	Although rather large variation in 
the results of these tests was obtained (particularly 
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with the 100 mg/kgm drug dose) there was no evidence 
of markedly different responses to pyrimethaniine from 
those of the parent lines, among the product clones. 
In the present series of crosses involving 
pyrimethamine-resistance conducted at Edinburgh, no 
evidence has been obtained for genetic transfer among 
the parasites by "synpholia". The crossing technique was 
however not conducive to the occurrence of this phen-
omenon, as the two parent lines involved in the cross 
were not grown to high parasitaemias within the same 
rodent. 	Proof of this type of gene transfer, which 
was first reported by Yoeli, et al., (1969), rests on 
establishing the frequency with which resistance appears 
after the selection of pyrimethamine-sensitive parasites. 
In the system used by Yoeli and his co-workers a 
pyrimethamine-resistant P.b.vinckei parasite line and a 
pyrimethamine-senstive P.berghei parasite line, were 
grown together in a single mouse until a high level of 
parasitaemia was obtained. Thereafter the parasites 
were sub-inoculated into 12 hamsters and 6 of these were 
later observed to contain drug-resistant, P.berghei 
parasites. 
Digg ens (1970) demonstrated that pyrimethsaine-
resistant P.berghei could arise after exposure of 
sensitive parasites to the same level of drug as used 
in the study of Yoeli et al. In her study, Diggens rec-
orded that 1 out of 20 hamsters treated with drug 
yielded a resistant line. 	Although Yoeli and his co- 
workers give no figures for the frequency of deve]opment 
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of their 6 pyrimethamine-resistant lines, using the 
assumptions and observations concerning blood volume 
and erythrocyte counts obtained in this study, it is 
possible to estimate that more than 109 parasites were 
present in the original mixed infection at the time it 
was sacrificed, and that about 1010  parasites were 
subjected to drug treatment in the hamsters. It is 
suggested from the results of selection experiments 
report ed in this study that a population of 1010 para-
sites is quite likely to contain a pyrimethamine-
resistant mutant of spontaneous origin, and although 
the presence of six independant mutants in this size of 
population is highly improbable, the design of the 
experiment would allow all the resistant parasites to 
have originated from one resistant clone. 
In conclusion therefore, it will be seen that 
the evidence reported by Yoeli et al (1969) for the 
occurrence of synpholia is not entirely convincing. To 
demonstrate conclusively the occurrence of a gene 
transfer phenomenon such as synpholia, frequencies of 
development of resistance must be calculated. 
j4) Future DeveloDments in Genetic Studies 
Genetic studies of plasmodia can be expected 
to make significant contributions to malaria research 
at a number of different levels. A study of enzyme 
variation has already been suggested will be of use in 
supplementing and refining the morphological and physio. 
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logical criteria by which taxonomic division is made 
(Carter, 1973). 	This type of information should lead 
to a clearer understanding of the relationships between 
the human malaria parasite species, and the reasons 
underlying the distribution of malaria strains through-
out the world. 
It is also important to determine the genetic 
variation of experimental parasite material currently 
held in laboratories. Some of these parasite strains 
will have accumulated extensive variation during the long 
periods since their isolation from the wild. Uniformity 
of parasite populations is of great importance in many 
fields of malaria research. For example, the clearest 
results of host antibody and parasite antigen inter-
action will inevitably come fromstudies where the simplest, 
that is genetically uniform, antigenic stimulus is presen-
ted to the host immune-response system. 
It must be hoped that new techniques will become 
available to allow the investigation into the mutational 
or adaptation origins of malaria variants, such as drug-
resistance and virulence, to continue. In addition, a 
useful approach to investigate the molecular changes 
underlying a mutant character might come from reversion 
studies with mutagens (see page 97). At present an 
obstacle to the study of molecular changes associated 
with drug-resistance using this approach is the absence 
of a technique to isolate sensitive parasites from a 
predominantly drug-resistant parasite population, such 
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as the replica plating methods available to bacteriol-
ogists, other than the time consuming method of cloning 
and testing of parasite lines. 	In the present woik 
an attempt was made to develop such a technique by using 
differences in PAM requirements of pyrimethamine-resistant 
and sensitive lines. 	Although this preliminary study 
was unsuccessful, it might be possible to develop this 
method by using plasmodial strains with very marked 
differences in PAM requirements and by preparing a 
solid mouse diet completely free of PAM. 
Dihydrofolate reductases isolated from chick 
liver have been examined by electrophoresis on starch 
and polyacrylamide gels (Huennekens et a]., 1971). It 
might therefore be profitable to continue the study of 
the different types of pyrimethamine-resistant parasites 
obtained by examining the dihydrofolate reductases of 
pyrimethamine-resistant and sensitive parasites by 
electrophoretic techniques. An illustration of the type 
of information which genetic studies on drug-resistant 
parasite lines might produce is afforded by the results 
of Hutchinson (1971) on aminopterin- resis tan t bacteria. 
Aminopterin is an antifolate in the same class as 
pyrimethainine. 	In studies on Diplococcus pneumoniae, 
three different genetic classes of mutant have been 
isolated. 	These classes are; a common transport group 
in which genetic change results in reduced binding of 
the drug to the carrier component; a rarer class in which 
the amount of dihydrofolate reductase present is increased 
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or the affinity of dihydrofolate reductase for the 
drug is altered, and a third class in which resistance 
is due to a different, unknown mechanism. 
In higher organisms it is possible to locate 
a gross chromosomal alteration resulting in a pheno-
typic variant by cytological examination of the karyotype. 
In malaria parasites, however, there is still confusion 
as to the number of chromosomes in individual cells 
(Wolcott, 1954 & 1957 ; Bano, 1959; Canning & Anwar,1968 
& 1969; Howells & Davies, 1971 and Canning and Sinden 
1973) and in view of the difficulties of examining these 
chromosomes, it seems most unlikely that cytological 
studies will be able to contribute to the study of the 
genetic origins of specific variants such as pyrimethamine-
resistant parasites. 
The location of gene changes has been studied in 
other organisms, and drug-resistance has in some cases 
been found to be determined by cytoplasmic factors. 
Some classes of erythromycin-resistance in yeast (Thomas 
and Wilkie, 1968, and Cohen et al., 1970) and in 
Paramecium aurelia (Beale, 1969 and Beale et al., 1972) 
have been found to be determined by cytoplasmic genetic 
factors located in the mitochondria. In bacteria, 
classes of drug-resistance have been shown to be assoc-
iated with episomes or R factors which are cytoplasmic 
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(Watan&bFukasawa, 1961a, and Watanabe,1963). 	For 
studies on the location of genes it is necessary to carry 
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out reciprocal matings so that the influence of the cyto-
plasm, which is largely contributed by the macrogamete 
can be investigated. 	Thus to commence the study of 
the location of genes in plasmodia a technique is needed 
to separate micro- and macrogametes. However, when 
bacteria are exposed to the action of intercalating dyes 
such as ethidiuiu, acrif].avine or acridines, the R 
factors are degraded (Watanabe and Fukasawa, 1961b, and 
Mitsuhasi et al., 1961) and if the R factors were carry-
ing drug-resistance then the bacteria revert to drug 
sensitivity. Yeast cells are also susceptible to these 
agents which act by stopping mitochondrial synthesis and 
degrading pre-existing zuitochondrial DNA (Go].dring et al., 
1970, and Penman and Mahler, 1971). As the mitochondria 
of rodent plasmodia are not active during the tropho-
zoite stages of the life cycle of the parasite (Howells 
et a].., 1969 and Howells, 1970) it is possible that the 
use of intercalating agents might prove useful in the 
study of gene location in malaria. 
Other types of gene transfer should also be 
investigated further. Transduction, the phage mediated 
transfer of small sections of the bacteria genome from 
one bacterium to another, is caused by the production of 
a defective virus particle containing a few bacterial 
genes (reviewed by Hayes, 1964). Virus particles have 
been found in plasmodia (Terzakis, 1969), but as yet no 
investigation of this type of gene transfer operating 
between plasmodia has been made. In addition the 
122. 
studies on synpholia could be extended which would 
require calculating frequencies of the development of 
resistant lines under the conditions most conducive for 
this type of transfer. 
In summary, a number of different problems could 
benefit from genetic studies. Genetic studies on 
malaria should, however, provide valuable information 





The Standard PAJ3A Supplement to the Host Diet 
(1) Adoption of a 0,05% PAM supplement to the drinking 
Water of the host mice1 as a standard addition to their 
laboratory diet. 
During the initial stages of this research pro-
gramme, an attempt was made to identify a suitable 
technique for assessing parasite drug response for use 
in conjunction with genetic studies. 
A difficulty encountered in this work was the 
presence of a considerable amount of variation in the 
course of blood infections. 	For example, it was not 
uncommon to inoculate 10 C57 mice each with 106  para-
sites (by the intraperitoneal route in 50% v/v calf 
serum and Ringer's solution) and observe that while in 
8 of these mice infections became patent I to 2 days 
post-inoculum, the remaining two mice did not show 
circulating parasitaemias until 6 to 10 days post-
inoculum. On occasions when smaller inocula were used, 
for example 1O4 parasitised erythrocytes, one or two 
of the 10 mice inoculated failed to become infected 
up to 21 days post-inoculum, when the experiment was 
discontinued. 
Meabezof the department of Parasitology at the 
Liverpool School of Tropical Medicine suggested that 
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this type of result might be due to a PAM (p-amino 
benzoic acid) deficiency in the solid mouse diet used 
in the laboratory, and drew attention to the import-
ance of this food additive for plasmodial growth, as 
suggested by the results of Hawking (1953). 
At that time the laboratory mice at Edinburgh 
were maintained on a locally prepared rat cake called 
QUAYSIDE produced by McGregorc of Leith • This was 
supplied to the mice ad libitum as was tap water. 
Peters (1967) had increased the growth of P.chabaudi 
infections by supplementing their diet with PAM 
administered in the drinking water. In April 1970, the 
effects of various concentrations of PAM (added to the 
drinking water of the mice) on the course of P.b.yoelii 
blood infections was investigated. This was carried 
out as follows: 5 groups of 6 C57, 4-5 week old male 
mice were caged separately. Each group was assigned 
to one of 5 different concentrations of PABA, namely; 
zero, 0.00059, 0.005% 9 0.059 and 0.4%. The mice were 
also supplied with QUAYSIDE. Twenty four hours after 
commencing their PAM diets, the mice were each 
inoculated with 5 x 10 parasites (P.b.yoelii,  line 17X). 
The inoculations were administered by the intraperit-
oneal route, in 50% v/v calf serum in Ringer's solution. 
The parasites inoculated had been harvested from mice 
maintained without a PAM supplement. On days 2 9 4 
and 8 post-inoculum, tail blood smears were prepared 
from each mouse and an estimation of parasitaemia made 
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Fig.lO. Growth of Infections of Line 17X in mice maintained 
on different PABA supplements. 
Mean I, parasitaemia of infections in *6 C57 mice ± 2 SE against 
PABA concentration (for results of individual mice see Table 24, 
Appendix B). 
Key 
ti mean % parasitaemia on day 4 post inoculum 
® mean % parasitaemia on day 8 post inoculum 







Zero 	o 00005% 0.0057.0057. 04Z 
Concentration of PABA in 
drinking water. 
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(materials and methods, page 20). The mean results 
recorded for each group of mice are presented in 
Table 19 and figure 10, while individual mouse results 
are included in Table 30, Appendix B. 
As Table 19 demonstrates, line 17X exhibited 
higher mean parasitaemias on day 8 in all groups of 
mice maintained on PAM supplemented &inking water, 
than in the group of mice receiving tap water alone. 
The intermediate concentrations of PAM, namely 0.05% 
and 0.005%, were associated with the highest mean para-
sitasmias, whereas the 0.4% solution appeared to be less 
efficient at promoting parasite growth. 	In fact, 
excessive amounts of PAM (4 to 87-6) in the diet have 
been reported to cause suppression of parasitasmia with 
P.berghei infections (in rats - Hawking and Terry, 1957 
and in mice - Kretschmar, 1965) and with P.vinckei 
infections (in hamsters Adler and Foxier, 1961). 
Subsequently, Mr A. Oxbrow, also of the Protozoan 
Genetics Unit at Edinburgh University, carried out a 
series of experiments comparing the growth of parasite 
infections maintained on one of three diets, namely: 
1.) QUAYSIDE solid diet with a 0.05% solution of PAM 
in the drinking water; 
Dixon's 418 solid diet (used for malaria research 
at the Liverpool School of Tropical Medicine) either 
without a PAM supplement or 
with a 0.05% concentration of PAM in the drinking 
water. His results showed no significant differences 
Table 19 • 	an Parasitaeaia of groups of nice maintained on varying concentrations of PABA 
Parasite No. of Parasites 
strain 	inoculated day 0 
by intrapentoneal 
route  
Concentration of PABA 
in the drinking water 
Estinates of Parasitaemia + S.E. 
Mean results of each group of 6 nice 
Day post-iicu1ua:- 
2 4 8 
17X 	5 x io 6 zero 0.05 1- 0.02 0.88 + 0.05 1.87 + 0.26 
0.0005% 0.08 + 0.03 1.25 + 0.22 3.55 + 0.60 
0.005% 0.10 + 0.02 0.95 + 0.09 3.08 + 0.50 
0.05% 0.12 + 0.02 0.84 + 0.11 4.37 0.64 
0.4% 0.07 + 0.02 0.90 + 0.11 2.30 + 0.26 
The individual parasitaaaias exhibited by nice in this experiment on days 2 9 4 and 8 post-
inoculun are included in Table 30. Appendix B. 
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in parasite growth in mice maintained on any of 
these diets (Oxbrow 1970: unpublished results). 
It was decided therefore to standardly maintain 
all laboratory mice on a 0.05 solution of PAM in 
tap water, in conjunction with the QUAYSIDE solid mouse 
diet. Mice were placed on this diet as soon as they 
entered the laboratory, and at least 7 days were 
allowed to elapse before they were inoculated with 
parasites. 
This regime has proved satisfactory and is used 
by all the workers in the Edinburgh laboratory for the 
standard maintenance of strains. However, on occasions 
an infection in one mouse in a group inoculated with a 
standardized inoculum size has been found to become 
patent several days after the rest of the group. It 
is considered that this could be due to faulty inocul- 
ation technique host variation or PAM factors. 	The 
rather low parasitaemias recorded on day 8 post-
inoculum in the original experiment to study the effect 
of PAM on the growth of line 17X have, in subsequent 
passages increased, presumably as a result of contin-
ually maintaining the line with a PAM supplement. 
It has never proved necessary to supplement the 
diet of Grammomys surdaster with PAM. These rodents 
were also maintained on QUAYSIDE, and with tap water 
supplied ad libitum with a constant supply of pieces 
of fresh apple. 
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(2) Parasite growth with a 0.05% solution of PAM 
8!42g-lementing the QUAYSIDE solid mouse diet. 
For a detailed comparison of the growth rates of 
different parasite lines, it would be necessary to 
grow all the lines simultaneously in the laboratory 
to minimise batch variation of the solid food. This 
was not carried out with the parasite lines used in 
this research programme after April 1970 when it became 
customary to maintain all laboratory mice on a 0.05% 
PAM supplement. 
To obtain exactly comparable results for a series 
of parasite lines it would also be necessary to stand-
ardise the recent laboratory histories of these lines, 
as it is well known that such factors as the number 
of blood passages since mosquito transmission would 
affect the growth characteristics of a particular line. 
However continued handling of the 9 parasite lines used 
in this study allowed their growth characteristics, 
after recent mosquito transmission to be separated into 
two distinct types: 1) those lines which grow in mature 
and immature erythrocytes and which generally kill 
their hosts and 
ii) those lines which usually infect reticulocytes and 
which even if they do eventually reach moderately 
high levels of parasitaeraia rarely kill their hosts. 
The day on which the first type of parasite line 
kills its host or the second reaches its maximum para-
sitaemia will depend upon such factors as the strain and 
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age of the mice and the state of development of their 
immunological responses, the size of the original 
parasite irioculum and in the case of some infections on 
the proportions of various types of red blood cells 
in the host's blood. 
An illustration of these two types of parasite 
growth characteristics are given in Table 20. These 
results are derived from one experiment when 10 
6 para-
sites of either line 33X or 33X(Pr3) were inoculated 
in 50% v/v calf serum in Ringer's solution by the intra-
peritoneal route on day 0, into 5 week old, male C57 
mice. 
Examples of initial growth patterns of P.b.yoelii 
and P.b. nigeriensis parasite infections in mice 
receiving a 0.05 PABA supplement (i.e. the period 
between inoculation and the recording of a 1% parasit-
aeaia have been included in Table 21 in view of the 
importance of this part of the parasite growth pattern 
for modified Warhurst drug tests. 
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Table 2]. Initial Grgwth Patterns of P.b.yoe].ii & P.b. 
nigeriensis Parasite infections initiated with 
parasites on day 	the intpeitonea1 route. 
Parasite Mouse Date of Mouse % Parasitaemias 
line host inocul- No. Day post.-inoculua:- 
ation 1 2 3 	4 	5 
33X C57 28.7.71 1 0.15 2.1 
2 0.17 1.6 
3 0.33 2.0 
4 0.36 2.4 
33X(Pr3) CS? 28.7.71 1 1.12 2.1 
2 0.29 2.3 
3 0.10 2.0 
4 0.24 1.4 
5 0.02 0.28 1.8 
33X(Pr4) C57 28.7.71 1 1.13 2.1 
2 0.12 2.4 
3 0.08 0.74 1.3, 
4 0.13 0.54 0.80 1.9 
1IX TO 10.8.71 1 0.15 1.1 
2 0.15 1.9 
3 0.11 1.9 
4 - 0.09 0.68 1.2 
N67 TO 10.8.71 1 0.01 0.30 3.2 
2 - 0.70 11.3 
3 0.01 0.55 3.2 
4 0.04 0.59 7.8 
33X TO 10.8.71 1 0.06 0.54 1.9 
2 - 0.66 2.4 
3 0.08 0.26 3.8 
4 0.08 2.86 4.3 
17X(Prl) TO 10.8.71 1 0.11 1.6 
2 - 0.09 2.08 
3 0.04 0.36 1.30 
4 0.05 1.3 
N67(Pr2) TO 10.8.71 1 0.02 0.35 3.9 
2 0.03 0.94 3.9 
3 - 0.20 2.8 
4 0.04 0.08 1.8 
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Parasite 	Mouse Date of Mouse % Parasitaeinias 
line 	host 	inocul. No. Day poet-inoculunit- 
ation 1 2 	3 	4 	5 
33X(Pr3) 	TO 	10.8.71 1 0.02 1.1 
2 0.05 0.62 5.4 
3 - 0.33 4.9 
4 0.01 1.3 
33X(Pr4) 	TO 10.8.71 	1 	0.02 048 5.4 
	
2 0.07 0.35 2.7 
3 	0.03 1.7 
4 0.08 006 5.2 
17X 	TO 18.10.71 1 	- 2.3 
2 0.05 1.6 
3 	0.01 0.34 3.3 
4 0.01 0.15 2.2 
7467 	TO 18.10.71 1 	0.03 0.07 1.0 
2 0.08 0.32 4.9 
3 	0.01 1.9 
4 0.04 0.05 1.5 
33X 	TO 18.10.71 1 	0.03 0.33 3.5 
2 0.04 1.07 
3 	0.01 1.7 
4 0.04 1.0 
17X(Prl) 	TO 18.10.71 1 	- 	- 0.12 5.0 
2 0.02 1.7 
3 	- 0.5 5.7 
4 0.01 1.6 
33X(Pr3) 	TO 18.10.71 1 	0.05 2.2 
2 0.06 1.6 
3 	0.05 2.0 
4 0.08 2.6 
17X 	TO 21.3.72 	1 	0.6 0.6 0.7 0.39 1.6 
2 0.3 0.83 3.5 
3 	- 	0.11 1.4 
4 0.09 1.0 
7467 	TO 21.3.72 	1 	0.05 0.87 6.0 
2 - 	0.50 0.22 2.6 
3 	- 0.03 2.5 
4 - 	0.32 7.3 
33X 	TO 	21.3.72 	1 0.01 0.14 1.7 
2 0.02 0.65 1.0 
3 0.08 0.76 4.8 
4 0.01 0.36 0.66 1.1 
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Parasite Mouse Date of Mouse 	S Parasitaeiuia 
line 	host inocul- No. Day postinoculum:- 
ation 	 1 2 3 4 5 
17X(Pr]) 	TO 21.3.73 	1 0.01 0.08 2.4 
2 	0.02 1.2 
3 0.03 1.0 
4 	0.02 0.67 2.5 
33X(Pr3) 	TO 	21.3.72 	1 0.11 1.0 
2 0.06 1.0 
3 0.04 1.7 
4 0.07 1.2 
33X(Pr3) 	TO 	21.3.72 	1 0.02 0.59 1.8 
2 0.01 0.73 4.0 
3 0.05 0.56 2.3 
4 0.03 0.34 5.0 
]IX 	TO 2.4.73 	1 	0.06 1.9 
2 0.05 3.3 
3 	0.04 1.8 
4 0.06 2.5 
17X(Prl) 	TO 2.4.72 	1. 	0,10 1,3 
2 0.04 1.0 
3 	0.02 2.3 
4 0.01 1.4 
33X(Pr3) 	TO 2.4.72 	1 	0.02 0.62 4.6 
2 - 	0.48 7.8 
3 	0.06 0.79 9.0 
4 - 	0.31 3.2 
33X(Pr4) 	TO 	2.4.72 	1 0.02 0.30 4.4 
2 0.16 3.8 
3 - 0.05 1.1 
4 0.42 3.6 
N67(Pr6) 	TO 	2.4.72 	1 0.05 2.9 
2 0.08 2.2 
3 0.09 1.3 
4 0.07 3.4 
N67 	TO 	21.8.72 	1 0.05 1.3 
2 - - 0.14 3.1 
3 0.01 1.5 
4 0.13 2.0 
N67(Pr2) 	TO 	21.8.72 	1 0.03 0.73 9.0 
2 0.05 0.39 5.7 
3 0.01 0.23 3.9 
4 0.04 0.80 7.3 
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Parasite Mouse Date of Mouse % Parasitaeaaia 
line host inocul- No. Day post-inoculunz:- 
ation 1 2 	3 	4 	5 
33X TO 21.8.72 1 0.02 1.5 
2 0.01 1.3 
3 - 0.32 2.8 
4 - 0,30 2,5 
17X(Pr5) TO 21.8.72 1 0.1.7 3.7 
2 0.06 5.4 
3 0.05 3.5 
4 0.14 3.4 
136. 
APPENDIX B 
Tables of individual mouse 
results 
137. 
Table 22. The effect of Ultraviolet Irradiation on 
parasite viability. 	(These results were used to prepare 
Fig.4, the Dose Response Curve). 
The time taken to reach a 17* parasitaezuia by individual 
X.O. Mice inoculated with aliquots of a concentrated 
parasitized erythrocyte suspension (line 33X) which had 
been treated with zero, 560, 16809 2800, 5000 or 7000 
ergs/nzm2 of U.V. 
Dose of Y.V. 	Time between inoculation and the 
(ergs/mm ) recording of a 1% parasitaemia:- 
Individual Mice Results 	Mean result +SE 
1 	2 	3 	4 
zero 1.4 1.0 1.6 1.4 1.4 + 0.25 
560 2.0 2.7 1.8 1.9 2.1 + 0.20 
1680 2.0 2.8 2.1 2.8 2.4 + 0.22 
2800 2.4 2.2 2.5 2.0 2.3 + 0.1.1 
5000 2.9 3.4 2.9 2.6 3.0 + 0,17 
7000 5.4 6.0 5.0 5.3 54 + 0,21 
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Table 236, Response to Pyrirnethamine 
The duration of 'test periods ,2 in  dividual infected 








Duration of 'Test Period' 
Dose of Pyrimethamine(mg/kgm) 
0 	2 	50 	75 
17X 	6 11.8.71 2.0 5.0 8.5 
1.8 5.3 7.9 
1.8 4.8 9.0 
3.8 4.0 8.1 
7 18.10.71 1.6 5.3 7.5 
1.7 3.1 7.1 
2.3 4.8 7.4 
2.5 2.4 7.3 
8 	21.3.72 	2.0 3.5 8.6 9.8 
2.8 3.3 7.5 9.0 
1.8 5.6 7.9 10.3 
2.2 4.5 8.1 (5) 
9 	17.8.72 	1.8 3.9 5.9 7.9 
1.7 5.5 5.9 6.9 
1.8 3.9 5.7 7.7 
1.7 2.7 5.6 7.6 




6 	11.8.71 	2.5 5.0 7.0 
2.1 6.1 7.6 
2.4 5.7 8.4 
2.2 6.0 6.8 
cont.. 
The above table is an expanded version of Tables 9a and 
9b respectively. In the latter tables only me*n results of 
each treatment group are recorded. 
For a definition of the 'test period' see Materials and 
Methods section page 33 
Each mouse was inoculated with 106  parasites, by the 
intraperitoneal route, on this day. 
Experiments 1-5 were carried out in CS7 mice, whereas 
experiments 6-9 were carried out in mice of the TO strain. 
In a number of cases insufricient mice were available for 
each drug treatment to be repeated in 4 mice. It was usual 
on these occasions to allocate only 3 mice to the group 
receiving the largest drug dose. 
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1467 7a 18.10,71 2,2 4,7 6.6 
cont. 1.8 7.0 7.4 
2.4 4.6 5.8 
2.1 4.7 7.1 
lb 18.10.71 2.0 3.5 018 
1.6 4.6 5.0 
1.5 3.1 
- 1.8 3.4 4.3 
8 21.3.72 2.0 3.5 7,6 7.9 
3,6 3.0 6.7 7.1 
2.3 4.0 7.7 7.7 
1.9 2.7 7.6 6.9 
9 17.8.72 1.9 3.4 6,4 6.8 
1.9 3.8 6.0 7.7 
1.7 3.9 5.6 7.6 
2.0 3.8 5.8 6.8 
33X 5 28.7.71 1.8 6.0 10.0 
1.9 4.6 7.7 
1.6 2.5 8.0 







3.3 5.0 7.5 
2,6 6.0 8.4 
1.7 5.1 8.2 
7 18.10.71 2.3 5.8 6.6 
1.8 53 8.0 
1.7 5.6 7.4 
1.9 4.5 6.7 
8 21.3.71 2.7 6.0 7.8 9.6 
2.9 5.7 7.8 9.9 
2.1 2.9 7.6 7.6 





6.0 7.3 10.2 
2.0 5.0 8.3 11.9 
2.5 4.1 11.7 9.7 
2.6 4.8 10.5 10.8 
17X(Prl) 1 
- 
23.5.71 2.9 2.1 
-----.-- .-.----.-...--'-----------.---- 
6.8 
3.0 3.8 5.8 
2.9 3.0 6.6 
1.0 2.7 7.4 






17X(prl) 4 	29.6.71 	1.8 2.0 
cont.. 1.8 2,6 
2.0 1.9 
2.0 2,3 
6 	11.8.71 	1.9 1.9 4.8 
2.8 1.9 4.9 
2.9 2.9 3.6 
1.9 3.4 (5) 
7 	18.10.71 	3.4 2.2 4.1 
1.6 1.7 2.2 
2 













































6 11.8.71 2.8 2.1 3.3 
2.6 2.1 3.0 
2.5 2.4 3.1 
2.0 2.4 2.7 
9 17.8.72 2.1 2,5 2.4 2.8 
2.4 2.1 2.4 3.2 
2.5 3.3 2.5 3.5 
2.3 3.1 2.5 2.9 
33X(Pr3) 5 28.7.71 1.:9 2.9 5.9 
2.3 2.3 6.0 
2.5 4.0 6.6 







2.5 2.6 5.5 
1.8 2.0 3.7 
2.2 2.1 2.8 
cont... 
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33X(Pr3)7 18.10.71 1.4 1.7 1.7 
cont.. 1.6 1.0 1.9 
1.6 1.0 1.7 
1.5 1.6 1.8 
8 21.3.72 1.9 1.7 1.7 2.1 
1.9 2.3 2.3 3.8 
1.8 2.1 2.1 2.2 
1.8 3.3 (5) 2.4 
8 21.3.72 2.4 2.5 2.7 2.9 
2.3 2.3 3.3 3.1 
2.1 1.9 3.9 3.1 
2.4 2.1 3.0 4.6 
9 17,8.72 2.2 2.1 3.1 38 
2.4 2.2 4.5 4.8 
2.1 2.3 2.5 4.5 
2.5 2.2 2.5 (5) 
33X(Fr4) 2.0 2.0 4.0 6 11.8.81 2.2 2.3 3.1 
2.4 2.2 3.2 
2.3. 2.2 2.9 
9 	17.8.72 	2.5 2.7 3.3 3.9 
2.6 2.1 3.0 5.0 
2.9 2.6 2.9 4.4 
2.4 2.6 2.8 4.1 
17X(Pr5) 9 	17.8.72 	1.6 1.9 2.9 5.0 
1.6 1.8 2.9 5.5 
1.7 1.7 3.4 4.8 
1.6 1.8 3.8 5.5 
N67(Fr6) 9 	17.8.72 	1.8 1.9 2.4 3.2 
1.8 2.1 2.2 3.4 
1.9 1.7 2.3 3.5 
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Table 24. 	 the effect o PAM on the growth 
of nine Darasite lin*s. 
Parasitasnias on day 4 post inoculun in 2 groups of nice, 
1 group being maintained with a PAM supplement (0.05% 
solution) in their drinking water. 
- ---.----- ---- -_--__i_-_--__•.'-_-____-_-_______-__------. -.-- 	________._.______.I__________.________- ---.-..- 
Parasite 	Addition M1  	to Host 'a Estinats of Psxasita.aii Day 
line 	drinking water 	4 post inQculuw. 
Mouse Nusber:- 
1 	2 	3 	4 
17X 	 PAM 4. V 4.1 6.0 3.1 
NONE 0.2 08 0.7 0.2 
N67 	 PAM 55 38 23 60 
NONE 7.5 0.5 0.0 0.0 
33X 	 PAM 6.3 5.8 7,4 2.3 
Nome 0.0 2.1 0.01 0.0 
LIX(Prl) 	PAM 3.8 Cj,7 4.4 7.9 
NONE 0.0 0.0 0.0 0.0 
N67(Pr2) 	PAM 32 33 42 39 
mom 0.0 7.7 0.7 03 
33X(Pr3) 	MM 65 58 44 49 
NONE 0.03 04 5.5 0.2 
33X(Pr4) 	PAM 6.4 8.5 12.5 10.9 
NGIL 0.0 0.0 01 2.0 
17X(Pr5) 	PAM 14 7.0 4.3 13 
NONE 2.8 001 0.1 0.7 
N67(Pr6) 	PAM 65 58 44 49 
NOW 
--------------------------------------------------------- 
0.03 0.4 0.2 5.5 
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Table 251  Response to Suiphadiazine 
The duration of 'test periods'2 in individual infected mice 
receiving zero (controls), 25, 125 and 500 mg/kgm of 
suiphadiazine. 
Parasite Exper- Date of Duration of 'TEST PERIOD' 
Line 	iment Parasite Dose of Suiphadiazine (mg/kgni) 
No. inocul- 
ation 3 0 25 125 500 
17X 	2 21.3.72 3.2 2.4 4.0 3.9 
1.8 2.7 3.5 3.4 
2.6 1.9 4.2 2.4 
1.8 3.0 3.8 2.5 
3 15.5.72 37 6.6 7.5 10.9 
4.6 5.9 7.6 10.6 
3.8 5.7 8.1 8.6 
3.2 6.0 8.1 8.9 
6 	17.8.72 	2.6 6.0 9.7 10.4 
1.9 6.7 10.1 10.7 
1.8 5.6 9.8 11.5 
2.6 6.2 10.3 12.7 
N67 	3 15.5.72 2.9 3.1 4.4 8.6 
3.5 4.4 4.5 8.7 
2.3 5.6 4.0 116 
2.6 4.9 4.6 4.5 
4 3.8.72 3.0 4.6 9.9 12.0 
3.8 4.5 11.9 11.2 
2.3 7.7 10.2 11.9 
3.0 7.7 11.0 12.8 
33X 	2 21.3,72 2.8 2.9 5.7 7.0 
2.0 4.1 7.0 9.0 
2.5 2.7 8.2 9.8 
3.0 3.0 5.9 8.4 
5 9.8.72 2.3 2.9 6.0 4.7 
1.8 3.3 4.7 5.8 
3.5 3.7 5.4 7.3 
2.7 4.7 5.2 6.4 
The above table is an expanded version of Table 11, page 67; 
in the latter table only mean results of each treatment group 
are recorded. 
For a definition of the 'test period' see Materials and 
Methods section page 33. 
Each mouse was inoculated with an estimated 106 parasites 
by the intraperitoneal route on this day. 
In this experiment insufficient mice were available for 
each drug treatment to be repeated in 4 mice. Therefore only 
3 mice were allocated to the group of mice receiving the 
largest drug dose. 
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Table 25 continued 
17X(Prl) 	1 	23.2.72 	3.2 3,7 8.0 9.0 
3.3 4.1 7.0 8.0 
3.0 4.7 7.9 7.9 
3.5 4.0 6.6 7.9 
2 	21.3.72 	4.1 3.8 5.8 4.7 
3.6 4.2 4.8 5.4 
3.1 3.6 6.0 5.5 
3.0 3.5 5.0 (4) 
6 	17.8.72 	2.8 5.4 8.8 
2.7 4.9 9.6 
2.8 48 9.8 
2.8 5.9 9.3 
N67(Pr2) 	3 	15.5.72 	2.8 4.6 4.8 4.9 
2.7 3.9 4.0 5.6 
2.5 4.3 4.6 5.9 
2.2 3.9 4.7 7.6 
4 	3.8.72 	3.8 4.6 10.9 11.5 
3.9 4.5 13.3 12.5 
3.7 3.7 11.3 11.3 
3.6 4.8 10.3 11.4 
33X(Pr3) 	1 23.2.72 	2.2 2.9 3.3 3.4 
24 3.2 3.2 3.4 
2.7 3,0 2.9 3.5 
2.2 2.6 3.3 3.3 
2 	21.3.72 	1.8 1.8 19 2.5 
2.0 2.2 3.8 2.4 
1.8 2.0 2.5 3.0 
1.9 2.2 1.9 2.3 
4 	3.8.72 	3.4 4.1 5.2 64 
3.2 4.4 4.8 5.8 
3.0 4.0 3.6 5.6 
3.2 4.7 4.9 4.6 
33X(Pr4) 	5 	9.8.72 	2.9 4.9 6.2 6.9 
2.6 4.2 6.7 6.8 
2.4 5.0 6.7 59 
2.3 5.1 5.5 6.0 
17X(Pr5) 	6 	17.8.72 	2.8 5.1 7.0 7.7 
1.9 6.0 6.6 7.6 
2.8 4.8 6.7 8.6 
1.9 5.7 6.9 (4) 
cont... 
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Table 25 cont... 
N67(Pr6) 	3 	15.5.72 	2.4 4.0 4.5 5.0 
3.0 4.0 4.8 7.0 
3.3 3.9 4.3 6.0 
3.0 4.3 3.8 5.9 
4 	3.6.72 	4.7 3.8 3.1 6.2 
3.0 6.0 4.9 6.1 
1.9 6.6 5.8 7.5 
3.0 5.2 5.8 7.4 
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Table 26a. kesponse t o Pyrimethamine of 7 clones derived 
from the prducts of a cross between line 17X(Prl) and 
line N67. 
The duration of "test periods"(2) 	individual, male, 
infected mice receiving zero (controls), 2, 50 and 100 
rng/kgm of pyriniethanzine. 
Parasite Date of Duration of "test period" 
Clone Parasite Dose of pyrimethaiuine (ag/kgm):- 
Number Inoculation(3) g 2 50 100 
1 2.3.72 2.0 2.1 6.1 6.5 
1.8 1.8 6.3 8.2 
1.6 2.3 6.4 7.8 
1.6 2.3 6.1 7.0 
2 2.3.72 2.1 2.6 5.7 6.9 
2.6 2.7 5.8 6.5 
3.1 4.0 5.8 6.4 
2.1 2.7 5.8 7.0 
3 	2.3.72 	1.9 1.5 2.7 5,5 
1.7 1.5 3.3 3.8 
1.5 1.4 2,7 3.1 
1.7 1.6 2.8 3.4 
4 2.3.72 1.7 1.7 3.1 3.6 
1.8 1.7 2.5 3.3 
1.9 1.6 3.0 4.2 
1.8 1.8 (4) 5.8 
5 2.3.72 1.7 2.2 6.4 5.8 
2.2 3.5 5.6 6.2 
1.6 3.8 6.3 5.3 
2.0 3.1 6.0 6.1 
6 2.3.72 3.0 1.8 4.0 4.4 
1.6 1.8 3.3 4.2 
2.1 2.0 4.3 4.7 
2.2 3.2 4.3 4,3 
7 2.3.72 2.2 1.7 3.1 3.6 
1.8 1.5 3.4 4.4 
1.7 1.7 2.9 4.7 
1.6 1.8 3.3 4.3 
The above table is an expanded version of Table 18, page85 
In the latter table only mean results of each treatment group 
of mice are recorded. 
For a definition of the 'test period' see Materials and 




Each mouse was inoculated with an estimated 106 
parasites by the intraperitoneal route on this day. 
In this experiment insufficient mice were available 
for each drug treatment to be repeated in 4 mice. 
Therefore only 3 mice were allocated to the group of 
mice receiving the largest drug dose. 
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jaoie 2ob. iauar presentation oi. Aesults in Fic.9. 
Response to pyriuethamine of 7 clones derived from the 
products of a cross between lines 17X(Prl) and N67. 
Cline Drug Increase in the 	'test 
No. 	Dose period' in comparison Limits of 	2S 
(mg/ with controls + SE 
kg)  
1 	2 0.3 + 0.16 0.0 - 0.6 
50 4.4 + 0.12 4.2 - 4.6 
100 5.6 + 0.40 4.8 - 6.4 
2 	2 0.5 + 0.41 -0.3 - 1.3 
50 3.3 0.24 2.8 - 3.8 
100 4.2 + 0.28 3.6 - 4.8 
2 0.2 + 0.09 0.0 - 0.2 
50 1.2 0.16 0.9 - 1.5 
100 2.3 + 0. 1.2 - 3.4 
4 	2 0,1 + 0.06 0.0 - 0.4 
50 1.1 0.18 0.7' -  1.5 
100 2.4 + U.b 1.3 - 3.5 
5 	2 1.3 + 0.38 0.5 - 2.1 
50 4.2 + 0.23 3.7 - 4.7 
100 4.0 + 0.25 3.5 - 4.5 
6 	2 0.0 + 0.45 -0.9 - 0.9 
50 1,8 0.38 1.0 - 2.6 
100 2.2 + 0.30 1.6 - 2.8 
7 	2 -0.1 + 0.14 -0.4 - 0.2 
50 1.4 0.17 1.1 - 1,7 
lOu 2.4 + 0.27 1.9 - 2.9 
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Effect of MBA on parasitrowth 
% Parasi tàóiii 4 post inocülui * 
ber type NO PAM 0.05% PAM Ratio 
Mouse number Mouse number 
1 2 3 1 2 3 
I R 1 0.75 0.40 0.0 1.9 2.0 3.2 1.6 
2 R 1. 0.0 0.06 0.07 1.8 1.6 1.7 2 
3 R 1 0.83 1.0 0.01 1.9 4.7 5.5 16 
4 R 1 0.32 0.30 0.0 2.3 8.4 4.2 3 
5 R 1. 0.01 0.02 0.12 3.4 3.0 3.0 2 
6 R 1 1.0 0.07 0.09 3.2 3.6 2.3 12 
7 R 1. 1.0 1.4 0.03 2.3 7.7 2.9 19 
8 R, 1. 1.2 0.01 0.0 4.6 3.9 2.6 19 
9 R 1 0.22 0.01 0.08 3.2 2.4 3.9 3 
10 R 1. 0.03 0.0 0.0 3.4 3.2 3.6 0 
11 R 1 0.06 0.12 0.05 5.2 9.8 3.0 13 
12 R 1 0.15 0.03 0.04 6.6 5.2 5.2 12 
13 R 1 0.03 0.24 0.09 10.1 5.0 3.0 2 
15 R 1 0.02 0.42 0.05 1.8 3.7 3.3 3 
16 R 1 0.35 0.01 0.05 3.7 2.9 4.7 3 
17 R 1 0.07 0.13 0.02 3.2 3.8 3.3 2 
18 R 1 0.0 0.24 0.04 4.3 2.9 1.3 10 
19 R 1 0.0 0.07 0.01 2.6 1.7 3.2 6 
20 R 1 0.0 0.05 0.09 2.3 2.8 4.2 2 
Ratio = mean parasitaemia day 4 poet inocu1m 
without PAM 
mean parasitaeia day 4joát 	um inocul 	x 100 
with a 0.0396 PAM supplement 
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Table 28. The characteristics of 20 clones derived from 
line 33X(Pr3) 
Clone Devel- GPI-
Nun- opment type 
ber type 
1. M&R 2 
2 M&R 2 
3 M&R 2 
4 M&R 2 
5 M&R 2 
6 M&R 2 
7 M&R 2 
8 M&R 2 
9 M&R 2 
10 M&R 2 
11 M&R 2 
12 M&R 2 
13 M&R 2 
14 M&R 2 
15 M&R 2 
16 M&R 2 
17 M&R 2 
18 M&R 2 
19 M&R 2 
20 M&R 2 
Effect of PABA 
% Parasitaemja d 
NO PAM 
Mouse number 
2.0 33 38 
14 28 1.6 
23 13 32 
3.5 6.5 31 
20 11 13, 
24 7.3 15 
23 24 14 
17 21 5.8 
9.6 9.9 30 
3.2 21 4.3 
8.2 60 14 
7.7 6.8 4.3 
3.3 39 8.0 
13 35 23 
7.7 24 34 
6.4 20 32 
65 13 6.8 
7.0 7.2 40 
5.1 20 8.0 
12 24 22 
on Growth 
y 4 post inoculu 
0.05% PAM 
Mouse number 
1 2 3 
53 38 45 
17 22 37 
31 17 25 
37 22 15 
22 17 28 
34 25 52 
45 26 27 
41 58 13 
17 36 15 
35 32 12 
38 48 46 
32 16 2.7 
18 43 68 
60 66 50 
36 5.9 46 
31 53 42 
50 24 62 
13 30 25 
14 19 34 






















*Ratio = mean parasitaemia day 4 post-in3culum 
without PAM 	 x ice 
mean  
with a 0.05% PAM supplement 
10 8.8 8.7 
3.8 7.2 3.7 
0.06 0.0 0.01 
16 0.52 0.78 
2.0 6.3 8.0 
0.09 1.4 0.20 
2.6 39 20 
31 63 9.0 
11 15 14 
19 45 51 
9 10 12 
13 14 12 
4.4 20 15 







7.9 1.0 5.0 
0.46 0.50 0.40 
1.9 6.4 1.1 
16 4.3 20 
0.0 0.0 0.0 
6.7 12.6 6.2 
3.2 2.7 3.0 
0.0 0.44 0.08 
3.1 0.05 0.14 
15 11 3.2 
10 7.0 7.3 
2.9 2.9 12 
6.0 5.1 8.0 
17 21 12 
0.6 23 25 
5.9 3.6 14 
19.6 36 25 
0.0 5.0 16 
10 19 
5.2 15 6 
33 24 41 











4.4 18. 1 28 
4.7 10 14 
4.1 1.3 44 
3.5 3.6 14 
11 4.0 38 




















Table 29. Characteristics of 40 clones derived from the 
products of a cross between lines 17X and 33X(Pr3). 
Clone Sensit- Devel- GPI 
Nun- ive or opment type 
ber Resis- type 
tan t 
Effect of PAM on parasite growth 
% 
 
parasitaemia 	Day 4 post 	I 	* 
inoculum Ratio 
NO PAM 	0.05% PAM 
Mouse number Mouse number 
1 	2 	3 	.1 	2 	IR 
1 Res M&R 1. 
2 Res M&R 1 
3 Res M&R 2 
4 Res M&R 2 
5 Res M&R 2 
6 Res M&R 2 
7 Res M&R 2 
8 Res M&R 2 
9 Res M&R 2 
10 Res M&R 1 
11 Res M&R 2 
12 Res M&R 2 
13 Res M&R 1 
14 Res M&R 1 
15 Res M&R 1 
16 Res M&R 2 
17 Res M&R 2 
18 Res M&R 2 
19 Res M&R 2 
20 Res R 1 
21 Sens R 2 
22 Res M&R 1 
23 Res M&R 2 
24 Res M&R 2 
25 Res R 1 
26 Res M&R 2 
27 Res M&R 2 
28 Res M&R 1 
29 Res V 1 
30 Res M&R 2 
31 Sens R 2 
32 Res M&R 1 
33 Res M&R 2 
34 Res R 2 
35 Res M&R 2 
36 Res M&R 2 
37 Res M&R 2 
38 Res M&R 2 
39 Res V 1 
40 Sens R 2 
12 0.4 16 38 30 48 24 
4.6 2.0 0.27 19 	18 17 	13 
20 22 6.7 21 14 16 94 
*Ratio = % parasitaemia day4ppst-inoculum without PAM 
% parasitaemia day 4 post-inoculum with a 	x 100 
0.05% PAM supplement 
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Table 30. Parasitaemias recorded in mice maintained with 
varying concentrations of PABA added to their drinking water. 
(Parasite line is P.b.yoelii, lIX; infections initiated 
with an inoculum size of 5 x 10 parasites; for further 
details of the experiment see Appendix A). 
Concentration Mouse Estimates of Parasitaeinia 
of PABA in Number Individual results from 6 infect- 
drinking ions in mice. 
water Day post-inoculum:- 
2 4 8 
0 1 0.07 0.97 1.5 
2 0.01 0.83 1.4 
3 0.02 0.88 2.6 
4 0.07 0.67 2.7 
5 0.04 0.91 1.2 
6 0.12 1.02 1.8 
0.0005% 1 0.05 1.90 3.8 
2 0.20 1.28 3.1 
3 0.06 1.74 5.6 
4 0.02 1.14 3.8 
5 0.07 1.09 3.9 
6 0.10 0.37 1.1 
0.005% 1 0.10 0.81 5.3 
2 0.09 1.24 2.0 
3 0.16 0.62 3.6 
4 0.16 097 2.2 
5 0.08 0.95 2.4 
6 0.02 -1.10 3.0 
0.052 1 021 1.34 6.6 
2 0.17 0.82 3.6 
3 0.09 0.90 2.2 
4 0.10 0.77 5.6 
5 0.06 0.61 4.4 
6 0.07 0.63 3.8 
0.4% 1 0.03 0.71 2.1 
2 0.03 0.66 1.8 
3 0.12 1.03 3.0 
4 0.07 0.71 2.8 
5 0.05 1.36 2.7 
6 0.12 0.91 1.4 
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APPENDIX C 
1. Comparison of Two Samples of Unequal size using 
Student's 't' test. 
(The 't' test formula was obtained from the statistics 
course Notes of Dr R.C.Roberts of the Institute of 
Animal Genetics, Edinburgh University. The 't' test 
was developed by Gosset (1908).) 
The question asked in this test is "could both 
samples be random samples drawn from the same population?" 
To obtain a measure of the difference to be 
expected from the means of samples drawn at random from 
the same population it is necessary to calculate the 
sampling variance of a difference. 
Thus, if the means of the two samples to be 
compared are R and 




where d2 = the population variance 
1 n2 are the sizes of the two samples. 
An estimate of the population variance can be obtained 
from the 2 original samples 
V 	+ 
(n1- l) 	(n2-l) 
155. 
2 2 = 	xl  + x2  
+ - 2 n2  
where x, and x are the "sums of squares" of the 
two original Samples. 
Substituting this estimate of the population 
variance into the previous formula 
V( 	 V(+.) 
- 
t(n1 + n2 -2) = X1 -X2  
V 	- X2) 
where the subscript to t is the appropriate degrees 
of freedom. 
15. 
'It" tests carried out 
The time taken by all the parasite lines to reach 
a 1% end point in the modified Warhurst drug tests 
in C57 mice, on a 0.05% PABA supplement (Table 23) 
has been compared with the time taken by the parasite 
lines to reach this end point in modified Warhurst 
drug tests in C57 mice on a 0.005% PABA supplement 
(Table 25). The comparison was made between the growth 
rates of "control" mice which did not receive drug 
treatment. 
Results of the "t" test:- 
Sample 1 Sample 2 
PABA supplement: 	 0.005% 	0.05% 
means of samples: R and X2 	 2.98 	2.37 
"sums of squares":x and 	638.40 	177.32 
number in samples: n1 and n 2 	72 	32 
t = 2,63 
df = 102 
p a 1% 
Therefore, only once in a 100 times would the difference 
observed between the sample means be expected to arise 
by chance if both samples had been drawn from the same 
population. 
To avoid comparing the growth rates of a mixture of 
lines, a "t" test was carried out on the results of 
157. 
drug tests with 17X(Prl). This parasite line was chosen 
as it was the one with which the largest number of 
drug tests had been carried out in C57 mice. Again 
the individual results of the infections on 0.05 and 
0.005% PAM supplements, in C57 mice not receiving drug 
treatment which constituted the two samples for com-
parison are to be found in Tables 23 and 25, in 
Appendix B. 	Results of the 'It"  test: 
Sample 1 Sample 2 
PAM supplement 0.005% 0.05% 
means of samples: R1 and 3.1.6 2.26 
"sums of squares": _x  and x 121.57 63.15  
numbers in samples: n1  and n2  12 12 
t a 0.23 
df = 22 
p 
Therefore more than once in 10 times would one expect 
to obtain a difference of this size in the sample 
means by chance alone. 
2. Mean increase in "test periods" for individual, parasite 
lines: pooling of experimental results. 
To pool the results obtained from a number of 
repeated drug tests, the mean time between inoculation 
of parasites and recording of a 14 parasitaemia by the 
control (undrugged) mice was subtracted from each mouse 
result in the drug treated groups within the same 
158. 
experiment. These adjusted results were then pooled 
between experiments for each drug treatment and the 
standard errors of the mean calculated as usual:- 
standard error = IWn— 
where v = variance 
* number in sample. 
3. The calculation of standard errors attached to the 
increase in "test period" within individual experiments. 
The calculation of the standard errors attached 
to the increase in "test periods" within experiments 
was carried out by summing the standard errors attached 
tc the mean "test periods" of control (undrugged) and 
each drug-treated group of mice, as follows:- 
1 	u2 
vl  standard error= I - + - 1 
where 
standard error 	standard error attached to increase 
in "test period". 
V1  and n1 	 = variance of "test period" results, 
and number of mice in control 
(undrugged) group. 
V2  and n 	 = variance of "test period" results, 
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Effect of PABA and Sulphadiazine on two pyrimethamiresjtant  
F1ainodiwn bcrthci yoelij lines 
ft-I-, ,- 
Sonia lorgan 
Institute of Animal Genetics, Vest lains Road, Edinburgh. 
Two lines of .b,yoelii originating from strains 17X and 33X have 
been made resistant to pyriznethamin using the single-step method of 
Diggenz (1970). 
Strain 33X was irradiated. with 5000 ergz/mm2 U.V. prior to the 
selection procedure. 
The resistant lines are termed. 17X(Pr1) and X(Pr3). 
Like other pyrimethamlno-resistant lines (Jacobs I 964.), line I 7(Prl) 
has a slightly increased dependence on p-aininobenzojo acid. (PABA) for its 
growth when compared to the sensitive parent strain. The growth rate of 
limo 35X(Pr3) was round to be independent of PAM Supplementation. 
Unlike other P.berj- hej lines selected for reitane to 	imcthajno 
(Peters 1970), line x(Pr3) was found to be cross resistant to suiphadiazine. 
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Jacobs, R.L. (1964.). 4xpl. Parasit., j, 213-225. 
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(Reprinted from Nature, Vol. 232, No. 5312, pp. 561-562, 
August 20, 1971) 
Genetic Recombination in 
Malaria Parasites 
THE complexity of the life cycle of malaria parasites and the 
lack of suitable strain characters which could be used as genetic 
markers have made genetic studies of these organisms difficult. 
We have now available, however, a number of strains of 
Plasmodium berghei isolated from wild rodents and mosquitoes 
in Africa, which can be differentiated from one another by 
starch-gel electrophoresis of certain enzymes'. We have also 
derived parasite lines resistant to the drug pyrimethamine from 
some of these strains, and such resistant lines remain stable 
even in the absence of the drug. By making crosses between 
lines which differ in both enzyme type and drug sensitivity, we 
have been able to obtain parasites exhibiting recombinant 
characters. 
The parasite lines selected for use are described here as lines 
A and C. Line A was derived from strain 17X of Pb. yoelii 
and is pyrimethamine resistant. The resistance was produced 
in a single step' by treating mice infected with strain 17X with 
pyrimethamine at doses of 50 mg/kg daily for 4 days. Line A, 
like strain 17X, contains the electrophoretic form of the 
enzyme glucose phosphate isomerase denoted GPI-l'. Line 
C was derived from strain 33X of Pb. yoelii, and is pyrimeth-
amine-sensitive. In the 4 day suppressive test', it is more than 
fifty times as sensitive to pyrimethamine as line A. Line C 
contains the enzyme form GPI-2'. 
The sequence in which this work was conducted is presented 
in Fig. 1. Equal amounts of blood (0.3 ml.) were taken from 
two tree rats (Grammomys surdaster), one of which was 
infected with line A and the other with line C. The blood from 
each animal was mixed and injected intravenously into an 
uninfected tree rat. This produced an immediate patent 
parasitaemia in the recipient (113 A + C in Fig. I). Mosquitoes 
(Anopheles stephensi) were fed immediately on this animal in 
the hope that gametes of each strain would mix. The resulting 
sporozoites were used to infect further tree rats from which ten 
C57 black mice (127 A + C in Fig. 1) were subsequently infected. 
Five of these mice were treated with subcutaneous doses of 
pyrimethamine" at 15 mg/kg daily for 4 days. All ten mice 
became infected and examination of the parasites on starch 
gels (Fig. 2) revealed the presence of both GPI-1 and GPI-2 in 
all animals. 
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Result:- 	GPI-1 	and 	GPI-2 	parasites 
present in all mice 
Fig. 1 Procedure adopted in producing recombinant parasites. 
To confirm that the GPI-2 parasites in the treated mice were 
drug-resistant, infected blood from these mice was diluted 
in serum Ringer' into aliquots containing an average of one 
parasitized cell. The aliquots were inoculated into individual 
mice, from which blood infections were established. Two 
GPI-1 and two GPI-2 lines were derived in this way, each of 
which was found to grow equally well when subjected to 
pyrimethamine treatment. 
As controls the parent lines A and C were passaged through 
mosquitoes, tree rats and mice in the same way as the mixture. 
Line A parasites survived drug treatment, and line C parasites 
were eradicated. The work has been repeated several times 
with similar results; line C has been exposed to pyrimethamine 
at doses of 15 mg/kg in fifty mice, none of which has remained 
infected. We think it very unlikely, therefore, that mutation 
could account for the appearance of resistant GPI-2 parasites 
in the mixed infections. 
Two further controls were set up to determine whether the 
recombinant parasites obtained were due to the phenomenon 
described by Yoeli et al.4 as "synpholia". In synpholia, it is 
suggested that pyrimethamine resistance can be transferred 
from one strain to another when they grow up together in blood 
lIP'! 
4
4~C' 717  
Fig. 2 Starch gel zymograms of glucose isomerase (GPI) 
in line A, line C, and mixtures of lines A and C. 1, Line A 
(GPI-0; 2, mixture following pyrimethamine treatment of 
mice 127A+C (showing GPI-1 and GPI-2); 3, mixture in 
untreated mice 127A+C (showing GPI-1 and GPI-2); 4, line C 
(GPI-2). 
cells of the same host. In the first control, tree rat 113A+C 
(inoculated with equal numbers of blood parasites of each line) 
was kept alive for 7 days after mosquitoes had fed on it. 
Blood parasites from this animal were then used to infect ten 
mice, five of which were treated with pyrimethamine. In these 
mice, only GPI-1 parasites survived, but in the untreated mice 
both GPI-1 and GPI-2 parasites were present. In the second 
control, sporozoites of each parent line were pooled and 
inoculated into tree rats. After five days, blood parasites from 
these animals were used to infect ten mice, five of which were 
given pyrimethamine. In untreated animals, both GPI-1 and 
GPI-2 parasites were detected, while the animals given pyri-
methamine contained only GPI-1 parasites after treatment. 
We have been unable, therefore, to produce parasites exhibit-
ing recombinant characters by simply mixing blood parasites or 
sporozoites of the parent lines. This does not disprove the 
phenomenon of synpholia, which may occur as a rare event 
detectable only when double selection pressure is applied', but 
suggests that it cannot account for our results. 
We consider that these results are important in two respects. 
First, they show that a conventional genetic analysis of malaria 
parasites is possible. This should enable us to obtain much 
more precise information than has been available hitherto on 
the biological basis of such important characters as drug 
resistance and virulence. Second, they indicate that genetic 
recombination is continually taking place in natural popula-
tions of malaria parasites, which enables the rapid evolution of 
new strains and their spread in populations of animals and man. 
We propose to exploit the technique outlined here to investigate 
the nature of other types of drug resistance as well as enzyme 
polymorphism and virulence. 
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